quinuclidines has been researched along with palonosetron in 338 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (1.18) | 18.2507 |
| 2000's | 77 (22.78) | 29.6817 |
| 2010's | 240 (71.01) | 24.3611 |
| 2020's | 17 (5.03) | 2.80 |
| Authors | Studies |
|---|---|
| Bonhaus, DW; Clark, R; Eglen, RM; Jakeman, L; Leung, E; Loury, D; Parnes, H; Whiting, RL; Wong, EH | 1 |
| Clark, R; Eglen, RM; Hegde, SS; Johnson, LG; Lee, CH; Smith, WL; Whiting, RL | 1 |
| Berger, J; Bonhaus, DW; Clark, RD; Eglen, RM; Kowalczyk, BA; Lee, CH; Michel, AD; Miller, AB; Repke, DB; Weinhardt, KK | 1 |
| Stacher, G | 1 |
| Aapro, M; Gralla, R; Labianca, R; Lichinitser, M; Macciocchi, A; Mezger, J; Peschel, C; Sleeboom, H; Tonini, G; Van Der Vegt, S | 1 |
| Cartmell, A; Charu, V; Eisenberg, P; Figueroa-Vadillo, J; Grunberg, S; Hajdenberg, J; Macciocchi, A; Zamora, R | 1 |
| Grunberg, SM; Koeller, JM | 1 |
| Cornett, PA; Eisenberg, P; Macciocchi, A; MacKintosh, FR; Ritch, P | 1 |
| Cyong, JC; Parisi, S; Shah, A; Stoltz, R | 1 |
| Scott, LJ; Siddiqui, MA | 1 |
| Rittenberg, CN | 1 |
| Trissel, LA; Xu, QA | 3 |
| Macciocchi, A; Parisi, S; Shah, A; Stoltz, R | 1 |
| Hussar, DA | 1 |
| Trissel, LA; Zhang, Y | 1 |
| Viale, PH | 1 |
| Ihbe-Heffinger, A; Lordick, F; Peschel, C | 1 |
| Cullen, MT; Gallagher, SC; Hunt, TL; Shah, AK | 2 |
| Rubenstein, EB | 1 |
| Olver, IN | 1 |
| Schwartzberg, L | 1 |
| Navari, RM; Province, PS | 1 |
| Lipp, HP | 1 |
| Board, R; Board, T | 1 |
| Fatigoni, S; Roila, F | 1 |
| Aapro, MS; Bertoli, LF; Grunberg, SM; Lordick, F; Macciocchi, A; Manikhas, GM; Morrica, B; Olivares, G; Suarez, T; Tjulandin, SA; Yunus, F | 1 |
| Santini, D; Tonini, G; Vincenzi, B | 1 |
| Padezanin, S | 1 |
| Awab, A; Chaudhary, L; Hamadani, M; Tfayli, A | 1 |
| Apseloff, G; DeGroot, T; Shah, A | 1 |
| Chen, H; Chen, X; Hu, Z; Tang, J; Tian, K | 1 |
| Cartmell, A; Charu, V; Ferguson, S; Ginkel, A; Grote, T; Hajdenberg, J | 1 |
| Navari, RM | 8 |
| Arevalo-Araujo, R; Grote, T; Hajdenberg, J; Latimer, LA; Yee, L | 1 |
| Chen, Y; Ding, L; Wen, A; Yang, L | 1 |
| McNulty, R | 1 |
| Urba, S | 1 |
| Herrstedt, J | 1 |
| Chowhan, N; Einhorn, LH; Hanna, NH; Johnson, CS; Loehrer, PJ; McClean, J; Navari, RM; Passik, SD; Vinson, J | 1 |
| Brames, MJ; Bubalo, J; Cullen, MT; Dreicer, R; Einhorn, LH; Nichols, CR | 1 |
| Ben, M; Kupiec, TC; Trissel, LA; Trusley, C | 1 |
| Wilkes, G | 1 |
| Eberhart, LH; Kranke, P; Schuster, F | 1 |
| Hamaguchi, T | 1 |
| Herrington, JD; Jaskiewicz, AD; Song, J | 1 |
| Andel, J; Angleitner-Boubenizek, L; Bernhart, M; Busch, K; Gehmacher, O; Hernler, T; Kastner, U; Lanz-Veit, A; Petru, E; Pluschnigg, U; Polachova, J; Rohde, M; Schiller, L; Schramböck, R; Stangl, W; Steger, G; Thödtmann, R; Zabernigg, A | 1 |
| Glass, PS; Lichtor, JL | 1 |
| Apfel, C; Clerici, G; Eberhart, L; Kotarski, J; Kovac, AL | 1 |
| Candiotti, KA; Clerici, G; Joo Gan, T; Kovac, AL; Melson, TI | 1 |
| Alt, J; Cantoreggi, S; Massuda, EB; Rojas, C; Rubenstein, E; Sebastiani, S; Slusher, B; Snyder, SH; Stathis, M; Thomas, AG; Zhang, J | 1 |
| Betanzos-Cabrera, Y; Del Angel, VW; Díaz, FC; Lastiri, GG; López-Aguilar, E; Rivera-Márquez, H; Sepúlveda-Vildósola, AC; Villasis-Keever, MA | 1 |
| Ellebaek, E; Herrstedt, J | 1 |
| Astara, G; Dessì, M; Lepori, S; Loi, C; Madeddu, C; Mantovani, G; Massa, E | 1 |
| Ben, M; Kupie, TC; Trissel, LA; Trusley, C | 1 |
| Devlin, PM; Khan, AJ; Siddiqi, NH | 1 |
| Huang, Y; Liang, H; Liu, D; Liu, W; Si, X; Wang, L; Yu, Z; Zhang, H | 1 |
| Bianchini, C; Bonanno, V; Crescimanno, A; Musso, M; Perrone, T; Polizzi, V; Porretto, F; Scalone, R | 2 |
| Burdette-Radoux, S; Dugan, M; Grunberg, SM; Muss, H; Siebel, M; Weisberg, T; Wood, M | 1 |
| Limebeer, CL; Litt, DE; Parker, LA | 1 |
| Aogi, K; Inoue, K; Kitagawa, C; Mitsuhashi, S; Ogura, T; Saito, M; Sakai, H; Sekine, I; Yanagita, Y; Yoshizawa, H | 1 |
| Pavesi, L; Sagrada, P; Zambelli, A | 1 |
| Di Maio, M; Perrone, F | 1 |
| De Jonghe, BC; Horn, CC | 1 |
| Giampaglia, M; Lorusso, V; Perrone, T; Petrucelli, L; Saracino, V; Spedicato, A | 1 |
| Eberhart, LH; Kranke, P; Wallenborn, J | 1 |
| Hida, T; Imamura, F; Katakami, N; Kubota, K; Maemondo, M; Masuda, N; Segawa, Y; Sekine, I; Shibuya, M; Takeo, S | 1 |
| Aogi, K; Atagi, S; Inoue, K; Isobe, H; Ogura, T; Sano, M; Segawa, Y; Sekine, I; Tokuda, Y; Tsuboi, M | 1 |
| Chen, H; Chen, X; Ding, X; Wang, M | 1 |
| Alt, J; Cantoreggi, S; Rojas, C; Rubenstein, EB; Sebastiani, S; Slusher, BS; Stathis, M; Thomas, AG; Zhang, J | 1 |
| Scott, LJ; Yang, LP | 1 |
| Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P | 1 |
| Chen, Q; Huang, C; Huang, J; Lin, T; Pan, L; Shen, H; Tian, W; Wang, J; Wang, Z; Zhang, L; Zhang, S; Zhou, J | 1 |
| Aapro, M; Bachmann, C; Fabi, A; Medici, M; Nolè, F; Roila, F; Roncoroni, S; Steger, G | 1 |
| Billio, A; Clarke, MJ; Morello, E | 2 |
| Herrstedt, J; Ruhlmann, C | 1 |
| D'Amico, MR; De Simone, G; Loffredo, G; Migliorati, R; Parasole, R; Petruzziello, F; Poggi, V; Ripaldi, M; Zanotta, G | 1 |
| Saito, M; Tsukuda, M | 1 |
| Fowler, B; Klinger, E; Matta, L; McDonnell, A; Reddy, P; Voit, D; Yeh, YC | 1 |
| Bria, E; Corona, M; Fabi, A; Lanzetta, G; Minniti, G; Nardoni, C; Restuccia, MR; Rozzi, A | 1 |
| Botrel, TE; Clark, L; Clark, OA; Faleiros, E; Paladini, L; Pegoretti, B | 1 |
| Altavilla, A; Cimadon, B; Cortesi, E; D'Antoni, I; De Luca, C; De Sanctis, R; Del Signore, E; Di Seri, M; Gamucci, T; Gori, B; Grande, R; Lapadula, V; Longo, F; Mansueto, G; Quadrini, S; Stumbo, L | 1 |
| Ardizzoia, A; Bajetta, E; Bertolini, A; Bichisao, E; Buonadonna, A; Capobianco, AM; Cavanna, L; Celio, L; Denaro, A; Fabi, A; Frustaci, S; Isa, L; Piazza, E | 1 |
| Cao, R; Dong, X; Huang, J; Liu, L | 1 |
| Goyal, A; Gupta, YK; Padhy, BM; Shanmugam, SP | 1 |
| Buda, G; Cantaffa, R; De Paolis, MR; Di Renzo, N; Dondi, A; Federico, M; Liardo, E; Mancuso, S; Mannina, D; Montanini, A; Muci, S; Olivieri, A; Patti, C; Plati, C; Stelitano, C | 1 |
| Ajioka, H; Akizawa, Y; Kitamura, R; Morita, F; Takimoto, H; Yoshida, K | 1 |
| Alt, J; Cantoreggi, S; Li, Y; Pietra, C; Rojas, C; Sebastiani, S; Slusher, BS; Stathis, M; Thomas, AG; Zhang, J | 1 |
| Apfel, CC; George, E; Hornuss, C | 1 |
| Beveridge, R; Bubalo, JS; DeGroot, TJ; Giralt, SA; Hurd, DD; Mangan, KF; Maziarz, RT; Mendoza, FL; Rubenstein, EB; Schuster, MW | 1 |
| Jain, A | 1 |
| Atri, R; Bhutani, G; Dhankar, R; Gupta, MC; Kaushal, J; Kaushal, V; Verma, S | 1 |
| Bekele, BN; Blamble, DA; Borthakur, G; Cabanillas, M; Cortes, JE; Kantarjian, H; Mattiuzzi, GN; O'Brien, S; Xiao, L | 1 |
| Likun, Z; Tao, ZL; Xiang, J; Xin, D; Yi, B | 1 |
| Aksu, R; Bicer, C; Boyaci, A; Dogan, H; Madenoglu, H; Ulgey, A; Yildiz, K | 1 |
| Bekker, A; Blitz, JD; Didehvar, S; Franco, L; Haile, M; Kline, R; Newman, E; Pachter, HL | 1 |
| Buchner, D; Cox, D; Hatoum, HT; Lin, SJ | 1 |
| Balu, S; Buchner, D; Craver, C; Gayle, J | 2 |
| Cho, EJ; Park, SK | 2 |
| Gu, Y; Lu, Z; Ou, N; Wang, Y; Zhang, P | 1 |
| Balu, S; Cox, D; Craver, C; Gayle, J; Morrow, G; Schwartzberg, L | 1 |
| Kumar, R; Mukkanti, K; Srinivas, K; Vishnu Murthy, M | 1 |
| Balu, S; Buchner, D; Jackson, J; Jain, G; Schwartzberg, L | 1 |
| Alterini, R; Bosi, A; Carrai, V; Caruso, JP; Landi, C; Perrone, T; Puccini, B; Rigacci, L | 1 |
| Balu, S; Buchner, D; Feinberg, B; Gilmore, J; Haislip, S; Jackson, J; Jain, G | 1 |
| Demirag, MK; Demircan, S; Erdem, D; Gonullu, G; Yucel, I | 1 |
| Aogi, K; Inoue, K; Katakami, N; Kuranami, M; Masuda, N; Mizutani, M; Sakai, H; Yanagita, Y; Yoshizawa, H | 1 |
| Pietkiewicz, JM | 1 |
| Bischoff, SC; Haub, S; Hubert, A; Ladel, I; Ritze, Y; Saum, K; Spruss, A; Trautwein, C | 1 |
| Gan, TJ; Klein, SM; Melton, MS | 1 |
| Li, F; Li, N; Qin, F; Wang, D; Xiong, Z; Yang, S | 1 |
| Basch, E; Chesney, M; Clark-Snow, RA; Feyer, PC; Flaherty, AM; Freundlich, B; Hesketh, PJ; Kris, MG; Lyman, GH; Morrow, G; Prestrud, AA; Rao, KV; Schwartz, RN; Somerfield, MR | 1 |
| Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A | 1 |
| Hiura, K; Komori, H; Sato, H; Suzuki, C; Yamamoto, M | 1 |
| Hesketh, PJ; Sanz-Altamira, P | 1 |
| Gao, HF; Liang, Y; Wu, HY; Zhang, DS; Zhou, NN | 1 |
| Araz, M; Ata, OY; Dogan, U; Yavas, C; Yavas, G | 1 |
| Basu, A; Hembrom, BP; Naaz, A; Roy, A; Saha, D | 1 |
| Abernethy, AP; Rangwala, F; Zafar, SY | 1 |
| Mamoudou, AD; Nadaraja, S; Rosthoej, S; Schroeder, H; Thomassen, H; Wehner, PS | 1 |
| Bassett, R; Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Kim, K; Mahoney, S; Noor, R; Papadopoulos, N | 1 |
| Joo, J; Kim, JE; Lee, Y; Moon, YE | 1 |
| Azevedo, W; Jacobs, P; Matsouka, P; Pinto, A; Schwartzberg, LS | 1 |
| Apfel, CC; Jukar-Rao, S | 1 |
| Li, P; Liu, L; Ma, P; Tong, W; Wang, J; Wang, Y; Wu, C | 1 |
| Chen, J; Gu, D; Jin, Y; Sun, W; Xu, Z; Yang, J | 1 |
| Giampaglia, M; Gnoni, A; Lorusso, V; Perrone, T; Petrucelli, L; Saracino, V | 1 |
| Pietra, C; Rojas, C; Slusher, BS; Stathis, M | 1 |
| Ata, OY; Dogan, U; Ozdemir, K; Tekinalp, M; Yavas, C; Yavas, G | 1 |
| Ahmed, R; Cox, D; Hesketh, PJ; Komorowski, AW; Morrow, G | 1 |
| Li, RC; Qiu, H; Zheng, LJ | 1 |
| Bekaii-Saab, T; Blazer, M; Efries, D; Griffith, N; Juergens, K; Phillips, G; Reardon, J; Rose, J; Smith, Y; Weatherby, L | 1 |
| Balu, S; Buchner, D; Cox, D; Hatoum, HT; Lin, SJ | 1 |
| Aapro, MS; Bajetta, E; Bonizzoni, E; Celio, L; Perrone, T; Sebastiani, S | 1 |
| Hayakawa, Y; Muro, K; Noma, H; Okamoto, H; Sato, Y; Tatematsu, M | 1 |
| Dakhil, SR; Heckler, CE; Kuebler, JP; Mohile, SG; Morrow, GR; Roscoe, JA; Wade, JL | 1 |
| Nakayama, Y; Shinohara, Y; Takahashi, K; Torigoe, T; Yamaguchi, K | 1 |
| Cho, I; Kim, KI; Lee, DE; Lee, HS; Oh, JM; Yoon, JH; Yoon, SS | 1 |
| Gray, SE; Nagy, CK; Navari, RM | 1 |
| Jo, YY; Kwak, HJ; Lee, MG; Lim, OK | 1 |
| Boccia, R; Franco-Gonzales, E; Grunberg, S; Rubenstein, E; Voisin, D | 1 |
| Fabi, A; Malaguti, P | 1 |
| Kubota, K; Saeki, T; Segawa, Y; Sekine, I | 1 |
| Cardillo, FD; Cognetti, F; Evangelista, S; Fabi, A; Fattoruso, SI; Pacetti, U; Veltri, E | 1 |
| Connolly, CN; Hothersall, JD; Moffat, C | 1 |
| Grunberg, SM; Rugo, HS; Slusher, B | 1 |
| Iwashima, A; Kagamu, H; Kobayashi, O; Makino, M; Miura, S; Miyao, H; Narita, I; Okajima, M; Sato, K; Tanaka, H; Tanaka, J; Watanabe, S; Yokoyama, A; Yoshizawa, H | 1 |
| Navari, R | 1 |
| Hatake, K; Ito, Y; Nakayama, Y; Takahashi, S; Tanabe, M | 1 |
| Agustoni, F; Celio, L; Damian, S; De Benedictis, E; De Braud, F; Mariani, P; Ricchini, F | 1 |
| Lummis, SC; Thompson, AJ | 1 |
| Calcagnile, S; Henriksson, A; Kammerer, KP; Lanzarotti, C; Rossi, G; Timmer, W | 1 |
| Berger, MJ; Blazer, MA; Crawford, BS; Flynn, JM; Griffith, NL; Layman, RM; Lustberg, MB; Mrozek, E; Phillips, GS; Ramaswamy, B; Shapiro, CL; Wenzell, CM; Wesolowski, R | 1 |
| Ballinari, G; Borsaru, GP; Choi, BS; Di Renzo, N; Voisin, D | 1 |
| Goto, H; Myojo, T; Osawa, H | 1 |
| Hu, SQ; Shi, HJ; Yang, HB; Yang, Z; Zhang, YH | 1 |
| Belli, C; Dahl, T; Herrstedt, J; Ruhlmann, CH | 1 |
| Blazer, M; Mori-Vogt, S | 1 |
| Abhyankar, S; Aljitawi, OS; Deauna-Limayo, D; Ganguly, S; McGuirk, JP; Wick, JA | 1 |
| Agustoni, F; Braud, FD; Celio, L; Dotti, K; Niger, M; Ricchini, F | 1 |
| Calcagnile, S; Giuliano, C; Lanzarotti, C; Mair, S; Nisbet, I; Rossi, G; Spinelli, T; Stevens, L | 1 |
| De Rienzo, F; Del Cadia, M; Lummis, SC; Menziani, MC; Thompson, AJ; Weston, DA | 1 |
| Choi, EK; Hong, DM; Jeon, Y; Jung, YS; Kim, HJ; Lee, HC; Lee, J; Min, JJ; Oh, S | 1 |
| Ballinari, G; Barbour, SY; Cox, D; Morrow, GR; Schwartzberg, L; Thorn, MD | 1 |
| Chun, HR; Jeon, IS; Kang, SH; Kim, SI; Lee, SJ; Park, SY | 1 |
| Hashimoto, H; Murakami, M; Senba, S; Siraishi, T; Yamaguchi, I; Yamaguchi, K | 1 |
| Bala, I; Bharti, N; Gupta, R; Murugesan, S | 1 |
| Bai, LY; Chiu, CF; Hsieh, CY; Liao, YM; Lin, CC; Lin, CY; Lin, PH; Lo, WC; Yeh, SP | 1 |
| Iwase, O; Nakajima, A; Nakamura, H; Okuyama, K; Takayanagi, R; Yamada, Y; Yokoyama, H; Yoshimoto, K | 1 |
| Kwak, YL; Roh, GU; Shim, JK; Yang, SY | 1 |
| Alkam, T; Chebolu, S; Darmani, NA; Vaezi, M; Zhong, W | 1 |
| Akashi, K; Arita, S; Ariyama, H; Baba, E; Komoda, M; Kumagai, H; Kusaba, H; Nagata, K; Nakano, M; Okumura, Y; Takaishi, S; Tamura, S; Uchida, M | 1 |
| Affronti, ML; Friedman, HS; Herndon, JE; Schlundt, S; Schneider, SM | 1 |
| Algarra, SM; Azanza, JR; Blanco Prieto, M; Campanero, MA; del Barrio, A; Gomez-Guiu, A; Guillén Grimá, F; Gurpide, A; Lopez-Picazo, JM; Perez-Gracia, JL; Sadaba, B | 1 |
| Blouin, GC; Reddy, P; Yeh, YC | 1 |
| Chan, KK; Chow, E; Deangelis, C; Lam, H; Poon, M; Popovic, M; Pulenzas, N; Tsao, M; Warr, DG; Yip, C; Zhang, L | 1 |
| Goto, T; Hara, S; Ikari, Y; Ishitsuka, K; Katsuya, H; Masaki, M; Nakashima, Y; Ogata, K; Sato, E; Takamatsu, Y; Tamura, K; Tanaka, T | 1 |
| Aapro, M; Bondarenko, I; Borroni, ME; Cardona-Huerta, S; Grunberg, S; Karthaus, M; Lorusso, V; Oprean, C; Rizzi, G; Rossi, G; Rugo, H; Sarosiek, T; Schwartzberg, L | 1 |
| Chang, KH; Chen, YK; Chou, CW; Hwang, WL; Teng, CL; Yu, YB | 1 |
| Alyasova, A; Bondarenko, I; Gralla, RJ; Hesketh, PJ; Lisyanskaya, A; Palmas, M; Rizzi, G; Rossi, G | 1 |
| Balser, C; Borroni, ME; Bosnjak, SM; Gralla, RJ; Hontsa, A; Jordan, K; Rizzi, G; Rossi, G | 1 |
| Arai, Y; Habuchi, T; Hamada, S; Hinotsu, S; Kamba, T; Kawai, K; Kawakami, K; Narita, S; Nishiyama, H; Ogawa, O; Yamada, S | 1 |
| Guo, WB; Guo, XM; Hu, SQ; Wang, GX; Zhao, M | 1 |
| Abe, M; Furuya, K; Hasegawa, K; Hirashima, Y; Itamochi, H; Ito, K; Kai, K; Kuritani, K; Matoda, M; Nasu, K; Otsuki, T; Sato, S; Takano, M; Takeshima, N; Terao, K; Tsubamoto, H | 1 |
| Gan, TJ; Klein, SM; Melton, MS; Nielsen, KC; Tucker, M | 1 |
| Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y | 1 |
| Andrews, PLR | 1 |
| Bonizzoni, E; Celio, L; Di Nicola, M; Gianni, AM; Magni, M; Mirabile, A | 1 |
| Rojas, C; Slusher, BS; Stathis, M; Thomas, AG | 1 |
| Choi, WJ; Hahm, TS; Hwang, JW; Kim, DK; Kim, WH; Kim, YH; Oh, EJ; Ryu, JH; Yon, JH; Yoo, BH | 1 |
| Fukahori, S; Fukuda, Y; Kitazaki, T; Kohno, S; Nakamura, Y; Oyanagi, K; Soda, H | 1 |
| Bee, LA; Dickenson, A; Greenwood-Van Meerveld, B; Mohammadi, E; Pietra, C; Tyler, K | 1 |
| Ahmed, SR; Candiotti, KA; Cox, D; Gan, TJ | 1 |
| Hanawa, S; Mitsuhashi, A; Nishikimi, K; Shozu, M; Tate, S; Uno, T; Usui, H; Watanabe-Nemoto, M; Yamamoto, N | 1 |
| Baek, CW; Choi, GJ; Jung, YH; Kang, H; Kim, JY; Moon, HY; Park, SG; Shin, HY; Woo, YC | 1 |
| Boccia, R; Cooper, W; Gabrail, N; Gralla, RJ; O'Boyle, E; Raftopoulos, H | 1 |
| Brygger, L; Herrstedt, J | 1 |
| Endo, M; Katsube, Y; Motohashi, R; Nakamura, K; Sato, H; Suzuki, M; Tsukahara, K; Ueda, Y | 1 |
| Aapro, M; Karthaus, M; Lorusso, V | 1 |
| Hori, M; Horie, S; Horiguchi, K; Iino, S; Kondo, M; Maehara, T; Matsumoto, K; Murata, T; Ozaki, H; Shimada, S; Tsubone, H | 1 |
| Guo, XM; Hu, SQ; Luo, RJ; Shi, HJ | 1 |
| Thompson, CA | 1 |
| Wang, SY; Yang, ZJ; Zhang, L | 1 |
| Aoki, Y; Hayashi, K; Higuchi, T; Igarashi, K; Inatani, H; Kato, T; Kimura, H; Nishida, H; Shimozaki, S; Shirai, T; Takeuchi, A; Tanzawa, Y; Tsuchiya, H; Yamamoto, N | 1 |
| Antony, J; Hemmelgarn, B; Hui, W; Hutton, B; Moher, D; Soobiah, C; Straus, SE; Struchkov, V; Tricco, AC | 1 |
| Chebolu, S; Darmani, NA; Mercadante, F; Zhong, W | 1 |
| Bianchi, S; Cappelli, S; De Luca Cardillo, C; Detti, B; Fambrini, M; Francolini, G; Furfaro, IF; Livi, L; Mangoni, M; Meacci, F; Meattini, I; Muntoni, C; Nori, J; Orzalesi, L; Scoccianti, S; Scotti, V | 1 |
| Borroni, ME; Filippov, A; Grunberg, SM; Karthaus, M; Lorusso, V; Rizzi, G; Rossi, G; Singh-Arora, R; Tibor, C | 1 |
| Kim, SH; Lee, SJ; Oh, CS | 1 |
| Gautam, S; Kaithwas, G; Kumar, A; Rawat, JK; Saraf, SA; Singh, M | 1 |
| Angelelli, L; Ballatori, E; Caserta, C; Cavanna, L; Ciuffreda, L; Colantonio, I; Fasola, G; Fatigoni, S; Fava, S; Ionta, MT; Licitra, L; Massidda, B; Mirabile, A; Palladino, MA; Roila, F; Ruggeri, B; Tocci, A; Zerilli, F | 1 |
| Hong, DM; Jeon, Y; Jung, HJ; Jung, SY; Kim, BG; Kim, HJ; Kim, TK; Kwon, K; Min, JJ; Park, BJ | 1 |
| Doi, A; Hirayama, M; Kitayama, H; Kondo, T; Sugiyama, J; Tsuji, Y | 1 |
| Eto, K; Fukushima, H; Furuhata, T; Isobe, H; Iwanaga, I; Kawamoto, Y; Komatsu, Y; Kudo, M; Masuko, H; Minami, S; Miyagishima, T; Nakajima, J; Nakamura, M; Oba, K; Ohsaki, Y; Okita, K; Sasaki, K; Shibuya, H; Takahashi, Y; Tateyama, M; Yokoyama, R; Yuki, S | 1 |
| Abramovitz, RB; Gaertner, KM | 1 |
| Furukawa, N; Ito, F; Kanayama, S; Tanase, Y | 1 |
| Chang, YJ; Jo, YY; Kim, YB; Kwak, HJ; Lee, D | 1 |
| Calcagnile, S; Cox, D; Kashef, K; Lanzarotti, C; Natale, JJ; Rossi, G; Spinelli, T | 1 |
| Horita, H; Hotta, H; Kato, R; Kitamura, H; Kunishima, Y; Masumori, N; Takahashi, A; Takei, F | 1 |
| Flaharty, KK; Moresino, C; Morganroth, J; Parisi, S | 1 |
| Abe, M; Hihara, H; Hirakawa, T; Hirashima, Y; Ichikawa, Y; Ito, K; Itonaga, Y; Kado, N; Kasamatsu, Y; Komeda, S; Kuji, S; Miyagi, K; Murakami, J; Nasu, K; Takahashi, N; Takekuma, M; Tanaka, A | 1 |
| Fujiwara, S; Kanemura, M; Ohmichi, M; Sasaki, H; Terai, Y; Tsunetoh, S | 1 |
| Hayakawa, O; Iwasaki, M; Matsuura, M; Mizunuma, M; Nishikawa, A; Saito, T; Satohisa, S; Tanaka, R; Tanaka, S; Teramoto, M | 1 |
| Baek, JH; Choi, YJ; Chung, JS; Joo, YD; Kim, HJ; Kim, YS; Koh, SJ; Lee, EM; Lee, HG; Lee, WS; Oh, SY; Seol, YM; Yun, EY | 1 |
| Boccia, R; Cooper, W; Gralla, RJ; O'Boyle, E; Raftopoulos, H | 1 |
| Liu, G; Ma, R; Wu, A; Xiong, C; Xue, J | 1 |
| Chang, YG; Lee, KB; Lee, WS; Lim, S | 1 |
| Enomoto, T; Katoh, H; Kikuchi, M; Kosaka, Y; Kuranami, M; Minatani, N; Nishimiya, H; Sato, T; Sengoku, N; Tanino, H; Waraya, M; Watanabe, M | 1 |
| Li, Y; Wei, X; Zhang, J; Zhang, S; Zhou, L | 1 |
| Aapro, M; Bosnjak, S; Hesketh, PJ; Jordan, K; Rugo, H; Schwartzberg, L | 1 |
| Fujimura, T; Fushida, S; Kadoya, N; Kaji, M; Kinami, S; Kinoshita, J; Nezuka, H; Ohta, T; Ohyama, S; Oyama, K; Takai, Y; Takeda, T; Tsuji, K; Tsukada, T; Tsukioka, Y; Yabushita, K | 1 |
| Kabanov, SN; Kalabanova, EA; Mitashok, IS; Storozhakova, AE; Svetitskaya, YV; Vladimirova, LY | 1 |
| Bala, I; Gandhi, K; Jain, D; Jain, K | 1 |
| Enomoto, N; Fujisawa, T; Hayakawa, H; Imokawa, S; Inui, N; Karayama, M; Koshimizu, N; Kuroishi, S; Kusagaya, H; Matsuda, H; Nakamura, Y; Shirai, T; Suda, T; Toyoshima, M; Yamada, T; Yokomura, K | 1 |
| Basharova, EV; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, AE | 1 |
| Ahn, HY; Bashaw, D; Griebel, D; He, R; Kim, I; Lee, SC; Mehrotra, N; Mulberg, A; Sinha, V; Sohrabi, F; Wang, J | 1 |
| Beydemir, Ş; Söyüt, H; Türkeş, C | 1 |
| Boccia, R; Cooper, W; O'Boyle, E | 1 |
| Christensen, TB; Dohn, LH; Feyer, P; Halekoh, U; Hansen, O; Herrstedt, J; Hilpert, F; Keefe, D; Kristensen, G; Paludan, M; Ruhlmann, CH; Rønnengart, E | 1 |
| Hou, F; Le, Q; Li, H; Li, W; Liu, S; Shi, Q; Zheng, L; Zong, S | 1 |
| Asano, C; Haegawa, I; Horio, Y; Kadowaki, S; Kajita, M; Komori, A; Maeda, A; Mizutani, A; Muro, K; Narita, Y; Nomura, M; Oze, I; Taniguchi, H; Ura, T; Yoshida, T | 1 |
| Hashizume, J; Higuchi, N; Kitahara, T; Kodama, Y; Matsunaga, N; Nakamura, T; Sakamoto, T; Sasaki, H; Sato, K; Yamaguchi, K | 1 |
| Liaw, CC; Wu, CE; Yang, CK | 1 |
| Aogi, K; Inoue, K; Kitagawa, C; Kubota, K; Ogura, T; Saito, M; Sakai, H; Sekine, I; Yanagita, Y; Yoshizawa, H | 1 |
| Ayuhara, H; Daimon, T; Hama, T; Hayashi, T; Hirai, K; Inoue, K; Itoh, K; Kogure, Y; Nakao, M; Nishio, M; Shibata, K; Suzuki, K; Takeda, K; Tsuji, D; Yokoi, M | 1 |
| Azuma, M; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Sasaki, T; Tanabe, S; Wada, T; Yano, T | 1 |
| Du, Q; Xu, XL; Yu, B; Zhai, Q; Zhu, B | 1 |
| Affronti, ML; Allen, K; Desjardins, A; Friedman, HS; Healy, PN; Herndon, JE; Kirkpatrick, J; McSherry, F; Peters, KB; Vredenburgh, JJ; Woodring, S | 1 |
| Hanawa, S; Matsuoka, A; Mitsuhashi, A; Nishikimi, K; Shozu, M; Tate, S; Uno, T; Usui, H | 1 |
| Chen, H; Du, J; Li, H; Li, S; Li, W; Ni, Y; Xu, M; Zhou, Y | 1 |
| Herrstedt, J; Ruhlmann, CH | 1 |
| Gralla, R; Jordan, K; Kashef, K; Rizzi, G | 1 |
| Arata, K; Azuma, K; Fujiwara, K; Goto, K; Hashimoto, H; Hayashi, T; Kogure, Y; Matsui, R; Nagase, S; Nakao, M; Nogami, N; Ohyanagi, F; Seki, N; Shimada, T; Shimada, Y; Suzuki, K; Takeda, K; Takiguchi, T; Yamamoto, N; Yamanaka, T | 1 |
| Bakar, JA; Chan, L; Chaw, SH; Foo, LL; Lee, PK; Rasiah, R | 1 |
| Fang, L; Hui, M; Liu, C; Quan, P | 1 |
| Fujita, A; Hatsuyama, T; Kobayashi, M; Sato, H; Sekine, K; Umehara, K; Wakamoto, A | 1 |
| Choi, SH; Jang, J; Kwak, YL; Shim, JK; Soh, S; Song, JW | 1 |
| Alice K, P; Badyal, D; Kwatra, G; Mukhopadhyay, S | 1 |
| Gomyo, H; Goto, H; Imamura, Y; Inui, Y; Ito, M; Kakiuchi, S; Kawamoto, S; Kitagawa, K; Kurata, K; Matsuoka, H; Minami, H; Minami, Y; Miyata, Y; Mizuno, I; Mizutani, Y; Murayama, T; Nomura, T; Sanada, Y; Sugimoto, T; Tominaga, R; Yakushijin, K; Yamamoto, K | 1 |
| Choi, EK; Jeon, Y; Kim, DG | 1 |
| Bang, YS; Kim, YU; Oh, D; Park, SK; Shin, EY | 1 |
| Lillestol, RK; Lummis, SC; Price, KL; Ulens, C | 1 |
| Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Takano, S; Yamamoto, T | 1 |
| Arora, MK; Borle, A; Gouda, D; Goudra, B; Makkar, JK; Singh, PM; Sinha, A; Trikha, A | 1 |
| Chu, LF; Clark, JD; D'Arcy, N; Encisco, EM; Erlendson, MJ; Peltz, G; Rincon-Cruz, L; Yu, JJ | 1 |
| Barras, M; Butler, JP; Curley, C; Kennedy, GA; Nakagaki, M | 1 |
| Abushouk, AI; Ahmed, H; Al Nahrawi, S; Attia, A; Awad, K; Elsherbeny, MY; Mustafa, SM | 1 |
| Fang, W; Hong, S; Huang, Y; Kang, S; Luo, Y; Sheng, J; Yang, Y; Zhan, J; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H; Zhou, N | 1 |
| Liu, Z; Ruan, L; Zhou, C; Zhu, Y | 1 |
| Ishikawa, T; Isoda, A; Komatsu, F; Manaka, A; Matsumoto, M; Miyazawa, Y; Negishi, Y; Oosawa, N; Saito, R; Sawamura, M | 1 |
| Aapro, M; Bondarenko, I; Borroni, ME; Cardona-Huerta, S; Hansen, V; Karthaus, M; Oprean, C; Rizzi, G; Rossi, G; Rugo, H; Sarosiek, T; Schwartzberg, L | 1 |
| Ahn, E; Baek, C; Chang, Y; Choi, G; Jung, Y; Kang, H; Lee, S; Woo, Y | 1 |
| Chen, H; Chen, LH; Chen, Z; Meng, ZQ; Ning, ZY; Xie, J; Zhang, CY; Zhu, XY | 1 |
| Furukawa, N; Ito, F | 1 |
| Ahn, EJ; Baek, CW; Choi, GJ; Jung, YH; Kang, H; Woo, YC | 1 |
| Chan, SW; Lu, Z; Rudd, JA; Subhan, F; Ullah, I | 1 |
| Dupuis, LL; Flank, J; Freedman, J; Gibson, P; Holdsworth, MT; Madden, JR; Orsey, A; Patel, P; Phillips, R; Portwine, C; Robinson, PD; Sung, L; Thackray, J | 1 |
| Choi, YS; Kim, MS; Park, JH; Park, SH; Shin, S | 1 |
| Gong, L; Hu, X; Tan, F | 1 |
| Basharova, E; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, A | 1 |
| Doggrell, SA | 1 |
| Isobe, T; Iwamoto, Y; Kaneko, M; Kenmotsu, H; Kikugawa, M; Koizumi, S; Mori, K; Murakami, H; Naito, T; Nakashima, K; Nishiyama, F; Omori, S; Ono, A; Takahashi, T; Wakuda, K; Yokoyama, K | 1 |
| Bao, Z; Liu, Q; Zhou, C; Zhu, Y | 1 |
| Guo, W; Guo, X; Hu, S; Liu, Q; Yang, Z; Zhang, Y | 1 |
| Bonizzoni, E; Celio, L; Croce, D; Di Turi, R; Nardulli, P; Perrone, T; Restelli, U; Saibene, G; Scolari, F | 1 |
| Abe, M; Arai, N; Ariizumi, H; Baba, Y; Fujiwara, S; Harada, H; Hattori, N; Kabasawa, N; Kawaguchi, Y; Murai, S; Nakamaki, T; Nakashima, H; Saito, B; Tsukamoto, H; Uto, Y; Yanagisawa, K | 1 |
| Adachi, K; Ikejiri, F; Inoue, M; Ito, S; Jo, Y; Kawakami, K; Kumanomido, S; Miyake, T; Okada, T; Okada, Y; Onishi, C; Suzuki, R; Suzumiya, J; Takahashi, F; Takahashi, T | 1 |
| An, Y; Chen, T; Chen, Y; Dong, Y; Fu, L; Jin, B; Jin, F; Jin, X; Liu, J; Liu, Y; Luo, Y; Man, L; Qu, J; Qu, X; Shi, J; Sun, T; Teng, Y; Teng, Z; Wang, J; Wang, Z; Wen, F; Xie, X; Yu, P; Yuan, C; Zhang, J; Zhang, L; Zhang, X; Zhao, M; Zhou, L; Zhu, Z | 1 |
| Akashi, K; Kadoyama, K; Kamezaki, K; Kato, K; Miyamoto, T; Mori, Y; Nakamura, T; Shiratsuchi, M; Takenaka, K; Uchida, M | 1 |
| Gourd, E | 1 |
| Deng, X; Kong, XR; Li, CC; Liang, X; Peng, L; Tan, J; Wang, S; Yang, C; Zhang, J; Zhao, Z | 1 |
| Ishiguro, T; Ogishima, D; Ota, T; Sugimori, Y; Ujihira, T | 1 |
| Arai, T; Hashimoto, H; Iwasa, S; Minato, K; Nagashima, K; Nakao, M; Nakayama, T; Ohyanagi, F; Sakai, H; Shimada, Y; Suzuki, K; Takeda, K; Takiguchi, T; Terakado, H; Yamamoto, N; Yanai, T | 1 |
| Hamakawa, H; Ibaragi, S; Kitamura, N; Kodani, I; Mishima, K; Miyamoto, Y; Nakashiro, K; Ryoke, K; Sasaki, A; Sento, S; Takamaru, N; Ueyama, Y; Yamamoto, T | 1 |
| Boccia, R; Calcanes, G; Caruana, D; McBride, A; Mosier, M; Vacirca, J | 1 |
| Hwang, JY; Jeon, YT; Min, B; Ryu, JH; Sohn, HM | 1 |
| Barnes, E; Chan, S; Chow, E; Chung, H; DeAngelis, C; Drost, L; Ganesh, V; Pasetka, M; Pulenzas, N; Tsao, M; Wan, BA; Yee, C; Zaki, P; Zhang, L | 1 |
| Chiu, L; Chow, R; DeAngelis, C; Lam, H; Milakovic, M; Popovic, M; Tsao, M | 1 |
| Celio, L; Fabbroni, C | 1 |
| Choi, JH; Jeon, JM; Kang, HY; Lee, S; Oh, ID; Park, SW | 1 |
| Badalamenti, G; Bazan, V; Casarin, A; De Luca, I; Incorvaia, L; Messina, C; Musso, E; Ricciardi, MR; Russo, A | 1 |
| Borroni, ME; Hansen, V; Jordan, K; Karthaus, M; Rizzi, G; Rossi, G; Rugo, HS; Schwartzberg, L | 1 |
| Berends, JC; Berkhof, J; Beusink, M; Brouwer, S; Toffoli, EC; van der Vorst, MJDL; van Linde, ME; van Voorthuizen, T; van Zweeden, AA; Verheul, HMW; Vrijaldenhoven, S | 1 |
| Anzai, Y; Ishida, Y; Kawahara, F; Kimoto, S; Kouuchi, A; Saito, N; Saito-Inoue, K; Watanabe, T | 1 |
| Bruera, E; Gallagher, C; Hui, D; Javle, M; Kaseb, A; Liu, D; Maddi, R; Overman, M; Puac, V; Shelal, Z; Yennurajalingam, S | 1 |
| Fujisaki, H; Goto, H; Hara, J; Ishida, Y; Koga, Y; Koh, K; Kosaka, Y; Kumamoto, T; Matsumoto, K; Mochizuki, S; Suzuki, R; Yuza, Y | 1 |
| Bertolini, F; Bonizzoni, E; Bria, E; Carnio, S; Cassano, A; Cavanna, L; Celio, L; Chiari, R; Cogoni, AA; Collovà, E; Cortinovis, D; De Placido, S; Gernone, A; Letizia, A; Martelli, O; Misino, A; Petrelli, F; Pilotto, S; Pisconti, S; Vittimberga, I; Zanelli, F | 2 |
| Bachet, JB; Bourgeois, H; Brocard, F; Chauffert, B; Debourdeau, P; Lefeuvre-Plesse, C; Leheurteur, M; Mayeur, D; Scotté, F; Simon, H; Wagner, JP; Zelek, L | 1 |
| Canale, FA; Console, G; Cusumano, G; Di Costanzo, A; Ferreri, A; Gallo, S; Gangemi, T; Irrera, G; Loddo, V; Loteta, B; Martino, M; Meliambro, N; Moscato, T; Naso, V; Paviglianiti, A; Porcino, D; Porto, G; Provenzano, PF; Pugliese, M; Romeo, V; Rossetti, AM; Russo, L | 1 |
| Abdul Rahman, MHFB; Abdullah, MM; Ahmad Annuar, MA; Ahmad Badruddin, RBA; Chong, KJ; Lai, CNB; Lam, KS; Lau, KL; Low, JSH; Md Yusof, M; Ng, SC; Nonis, JG; Yap, BK | 1 |
| Al Bawab, AQ; Al Shawakri, E; Al-Qawasmeh, B; Alhifany, AA; Alkhatib, NS; Halloush, S; Koeller, J | 1 |
| Lai, J; Li, C; Li, P; Li, Y; Li, Z; Rastogi, S | 1 |
| Aapro, M; Bonizzoni, E; Celio, L; Montani, E | 1 |
| Aapro, M; Eriksson, J; Lezzi, C; Nilsson, J; Piovesana, V; Turini, M | 1 |
| Chen, Y; Liang, J; Liu, S; Zhu, H | 1 |
| Bailey, WL; Navari, RM; Nelson, WW; Shoaib, S; Singh, R; Zhang, W | 1 |
| Egawa, T; Hayashi, T; Kawada, K; Matsuo, K; Nakano, T; Shimokawa, M; Uchiyama, M | 1 |
| Minotti, G | 1 |
69 review(s) available for quinuclidines and palonosetron
| Article | Year |
|---|---|
Palonosetron (Helsinn).
Topics: Animals; Antiemetics; Clinical Trials as Topic; Humans; Isoquinolines; Palonosetron; Quinuclidines; Serotonin Antagonists; Structure-Activity Relationship | 2002 |
Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Humans; Indoles; Isoquinolines; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2003 |
Palonosetron.
Topics: Antiemetics; Antineoplastic Agents; Humans; Injections, Intravenous; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2004 |
The next generation of chemotherapy-induced nausea and vomiting prevention and control: a new 5-HT3 antagonist arrives.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Isoquinolines; Male; Nausea; Palonosetron; Prognosis; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting | 2004 |
Integrating aprepitant and palonosetron into clinical practice: a role for the new antiemetics.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Humans; Isoquinolines; Morpholines; Nausea; Palonosetron; Practice Guidelines as Topic; Quinuclidines; Vomiting | 2005 |
[Antiemetic prophylaxis in the chemotherapy of gastrointestinal tumours].
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Drug Therapy, Combination; Gastrointestinal Neoplasms; Humans; Isoquinolines; Morpholines; Nausea; Palonosetron; Premedication; Quinuclidines; Treatment Outcome; Vomiting | 2005 |
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Cytochrome P-450 CYP2D6; Dexamethasone; Female; Half-Life; Humans; Indoles; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Palonosetron; Protein Binding; Quinolizines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2004 |
Update on anti-emetics for chemotherapy-induced emesis.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Australia; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granisetron; Humans; Indoles; Isoquinolines; Male; Neoplasms; Ondansetron; Palonosetron; Patient Satisfaction; Prognosis; Quality of Life; Quinolizines; Quinuclidines; Treatment Outcome; Tropisetron; Vomiting | 2005 |
Chemotherapy-induced nausea and vomiting: state of the art in 2006.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Humans; Isoquinolines; Medical Oncology; Morpholines; Nausea; Neoplasms; Palonosetron; Quality of Life; Quinuclidines; Vomiting | 2006 |
Emerging drugs for chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Antipsychotic Agents; Aprepitant; Benzodiazepines; Brain; Dexamethasone; Drug Therapy, Combination; Gastrointestinal Tract; Humans; Isoquinolines; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Receptors, Neurokinin-1; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vagus Nerve; Vomiting | 2006 |
The role of 5-HT3 receptor antagonists in preventing postoperative nausea and vomiting.
Topics: Adult; Algorithms; Antiemetics; Child; Dexamethasone; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Evidence-Based Medicine; Granisetron; Humans; Indoles; Isoquinolines; Nurse's Role; Nursing Assessment; Ondansetron; Operating Room Nursing; Palonosetron; Patient Selection; Postoperative Nausea and Vomiting; Practice Guidelines as Topic; Quinolizines; Quinuclidines; Risk Assessment; Risk Factors; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists | 2006 |
New antiemetic drugs.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug Therapy, Combination; Humans; Isoquinolines; Medical Oncology; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin Antagonists; Vomiting | 2006 |
New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron.
Topics: Animals; Antineoplastic Agents; Drugs, Investigational; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Vomiting | 2005 |
Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
Topics: Age Factors; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Risk Factors; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Sex Factors | 2006 |
Prevention of emesis from multiple-day and high-dose chemotherapy regimens.
Topics: Antiemetics; Antineoplastic Agents; Benzodiazepines; Drug Therapy, Combination; Humans; Isoquinolines; Metoclopramide; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2007 |
Radiation-induced nausea and vomiting.
Topics: Abdominal Neoplasms; Dexamethasone; Dose Fractionation, Radiation; Head and Neck Neoplasms; Humans; Isoquinolines; Nausea; Palonosetron; Practice Guidelines as Topic; Quinuclidines; Radiotherapy; Serotonin Antagonists; Thoracic Neoplasms; Vomiting | 2007 |
[Medical treatment of chemotherapy-induced nausea and vomiting].
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Dexamethasone; Drug Interactions; Drug Therapy, Combination; Evidence-Based Medicine; Ghrelin; Glucocorticoids; Granisetron; Humans; Isoquinolines; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Peptide Hormones; Practice Guidelines as Topic; Quinuclidines; Serotonin Antagonists; Vomiting | 2007 |
Recent advances, trends and economic considerations in the risk assessment, prevention and treatment of postoperative nausea and vomiting.
Topics: Algorithms; Antiemetics; Aprepitant; Dexamethasone; Drug Therapy, Combination; Humans; Isoquinolines; Morpholines; Neurokinin-1 Receptor Antagonists; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Risk Assessment; Serotonin Antagonists | 2007 |
[Gastrointestinal complication of cancer chemotherapy].
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Diarrhea; Humans; Isoquinolines; Morpholines; Nausea; Palonosetron; Quinuclidines; Risk; Serotonin Antagonists; Stomatitis; Vomiting | 2007 |
Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Dexamethasone; Dopamine D2 Receptor Antagonists; Drug Administration Schedule; Humans; Isonipecotic Acids; Isoquinolines; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2008 |
Antiemetic control: toward a new standard of care for emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Clinical Trials, Phase III as Topic; Humans; Isoquinolines; Morpholines; Nausea; Palonosetron; Piperazines; Piperidines; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
Palonosetron: in the prevention of nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Drug Interactions; Humans; Isoquinolines; Nausea; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
Topics: Animals; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2009 |
Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Topics: Adult; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2010 |
Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Vomiting | 2010 |
Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.
Topics: Animals; Antiemetics; Antineoplastic Agents; Dopamine Antagonists; Evidence-Based Medicine; History, 20th Century; History, 21st Century; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting | 2010 |
Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis.
Topics: Antiemetics; Antineoplastic Agents; Glucocorticoids; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2011 |
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
Topics: Antiemetics; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Risk Factors; Safety; Serotonin Receptor Agonists; Vomiting | 2010 |
[Pharmacological, pharmacokinetic, and clinical profile of palonosetron hydrochloride (ALOXI I.V. Injection 0.75 mg), a novel antiemetic 5-HT3-receptor antagonist].
Topics: Animals; Antineoplastic Agents; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Humans; Injections, Intravenous; Isoquinolines; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Rats; Serotonin Antagonists; Vomiting | 2010 |
Neurokinin-1 and novel serotonin antagonists for postoperative and postdischarge nausea and vomiting.
Topics: Ambulatory Surgical Procedures; Anesthesia; Antiemetics; Aprepitant; Humans; Isoquinolines; Morpholines; Neurokinin-1 Receptor Antagonists; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Serotonin Antagonists | 2010 |
A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults.
Topics: Adult; Antiemetics; Antineoplastic Agents; Constipation; Dexamethasone; Headache; Humans; Infusions, Intravenous; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting | 2011 |
Management of postdischarge nausea and vomiting after ambulatory surgery.
Topics: Ambulatory Surgical Procedures; Anesthesia; Antiemetics; Cholinergic Antagonists; Combined Modality Therapy; Dexamethasone; Glucocorticoids; Humans; Isoquinolines; Neurokinin-1 Receptor Antagonists; Palonosetron; Patient Discharge; Postoperative Nausea and Vomiting; Quinuclidines; Risk Factors; Serotonin Antagonists | 2011 |
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug Administration Schedule; Humans; Infusions, Intravenous; Isoquinolines; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Quinuclidines; Radiotherapy; Serotonin Antagonists; Surveys and Questionnaires; Vomiting | 2011 |
Gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, insights, and a proposed approach.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Gastrointestinal Diseases; Granisetron; Humans; Isoquinolines; Nausea; Neoplasms; Palliative Care; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting; Zingiber officinale | 2012 |
The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Half-Life; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Receptors, Serotonin, 5-HT3; Salvage Therapy; Serotonin 5-HT3 Receptor Antagonists; Stem Cell Transplantation; Transplantation Conditioning; Vomiting | 2012 |
Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
Topics: Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2013 |
Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase I
Topics: Adult; Age Factors; Aged; Anthracyclines; Antiemetics; Antineoplastic Agents, Alkylating; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Middle Aged; Multicenter Studies as Topic; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2013 |
An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.
Topics: Animals; Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Humans; Isoquinolines; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Practice Guidelines as Topic; Quinuclidines; Radiotherapy; Serotonin 5-HT3 Receptor Antagonists; Substance P; Treatment Outcome; Vomiting | 2013 |
Emerging treatments in chemotherapy-induced nausea and vomiting.
Topics: Allosteric Regulation; Antiemetics; Antineoplastic Agents; Humans; Isoquinolines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Palonosetron; Pyridines; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2013 |
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Antineoplastic Agents; Humans; Induction Chemotherapy; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2013 |
WITHDRAWN: Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Topics: Adult; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2013 |
Evidence to support use of palonosetron over generic serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drugs, Generic; Evidence-Based Medicine; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2014 |
Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials.
Topics: Antiemetics; Antineoplastic Agents; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin Antagonists; Vomiting | 2014 |
Long-acting serotonin antagonist (Palonosetron) and the NK-1 receptor antagonists: does extended duration of action improve efficacy?
Topics: Antiemetics; Humans; Isoquinolines; Neurokinin-1 Receptor Antagonists; Palonosetron; Patient Discharge; Postoperative Nausea and Vomiting; Quinuclidines; Serotonin Antagonists; Time Factors | 2014 |
5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
Topics: Aged; Antiemetics; Antineoplastic Agents; Cardiovascular Diseases; Granisetron; Humans; Isoquinolines; Long QT Syndrome; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2014 |
Palonosetron for the treatment of chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Isoquinolines; Nausea; Palonosetron; Quality of Life; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2014 |
Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Pyridines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Treatment Outcome; Vomiting | 2015 |
Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Dexamethasone; Emetics; Humans; Isoquinolines; Morpholines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quinuclidines; Vomiting | 2014 |
Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV).
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Isoquinolines; Molecular Structure; Nausea; Neoplasms; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2015 |
Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review.
Topics: Antiemetics; Antineoplastic Agents; Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Humans; Indoles; Isoquinolines; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists | 2015 |
The role of netupitant and palonosetron in chemotherapy-induced nausea and vomiting.
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin Antagonists; Vomiting | 2016 |
Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Dexamethasone; Drug Combinations; Drug Interactions; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; Serotonin Antagonists; Vomiting | 2016 |
Efficacy of palonosetron for preventing postoperative nausea and vomiting: a systematic review and meta-analysis.
Topics: Antiemetics; Humans; Isoquinolines; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Randomized Controlled Trials as Topic; Time Factors | 2015 |
A Meta-Analysis of Palonosetron for the Prevention of Postoperative Nausea and Vomiting in Adults.
Topics: Adult; Antiemetics; Humans; Isoquinolines; Middle Aged; Palonosetron; Placebos; Postoperative Nausea and Vomiting; Quinuclidines | 2015 |
A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting.
Topics: Antiemetics; Antineoplastic Agents; Guideline Adherence; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2015 |
Exposure-Response of Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Area Under Curve; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infant; Infusions, Intravenous; Isoquinolines; Logistic Models; Male; Nausea; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2016 |
Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Granisetron; Humans; Isoquinolines; Morpholines; Nausea; Neoplasms; Network Meta-Analysis; Ondansetron; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Spiro Compounds; Treatment Outcome; Vomiting | 2016 |
New treatments on the horizon for chemoradiotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Humans; Isoquinolines; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Receptors, Serotonin, 5-HT3; Vomiting | 2016 |
Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis.
Topics: Adult; Anesthesia, General; Antiemetics; Benzimidazoles; Granisetron; Humans; Isoquinolines; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin Antagonists; Treatment Outcome | 2016 |
Dexamethasone combined with other antiemetics versus single antiemetics for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: An updated systematic review and meta-analysis.
Topics: Antiemetics; Benzimidazoles; Cholecystectomy, Laparoscopic; Dexamethasone; Drug Therapy, Combination; Granisetron; Humans; Isoquinolines; Metoclopramide; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Randomized Controlled Trials as Topic | 2016 |
Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug Therapy, Combination; Humans; Isoquinolines; Morpholines; Nausea; Network Meta-Analysis; Neurokinin-1 Receptor Antagonists; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2017 |
5-HT3 receptor antagonists for the prevention of postoperative shivering: a meta-analysis.
Topics: Analgesics, Opioid; Granisetron; Humans; Indoles; Isoquinolines; Meperidine; Ondansetron; Palonosetron; Postoperative Complications; Postoperative Period; Quinuclidines; Randomized Controlled Trials as Topic; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Shivering; Surgical Procedures, Operative; Tropisetron | 2016 |
Palonosetron and Ramosetron Compared for Effectiveness in Preventing Postoperative Nausea and Vomiting: A Systematic Review and Meta-Analysis.
Topics: Benzimidazoles; Female; Humans; Isoquinolines; Male; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Randomized Controlled Trials as Topic | 2016 |
Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Infant; Isoquinolines; Male; Nausea; Neoplasms; Palonosetron; Practice Guidelines as Topic; Quinuclidines; Serotonin Antagonists; Vomiting | 2017 |
Efficacy of Palonosetron vs. Ramosetron for the Prevention of Postoperative Nausea and Vomiting: A Meta-Analysis of Randomized Controlled Trials.
Topics: Adult; Antiemetics; Benzimidazoles; Female; Humans; Isoquinolines; Male; Middle Aged; Palonosetron; Postoperative Nausea and Vomiting; Publication Bias; Quinuclidines; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2017 |
Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) - is there still a role after comparison with palonosetron?
Topics: Administration, Cutaneous; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Vomiting | 2017 |
Effects of palonosetron and ondansetron on preventing nausea and vomiting after laparoscopic surgery.
Topics: Anesthesia, General; Antiemetics; Humans; Isoquinolines; Laparoscopy; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Dexamethasone; Drug Combinations; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Palonosetron; Quinuclidines; Radiotherapy; Randomized Controlled Trials as Topic; Serotonin Antagonists; Vomiting | 2018 |
Evaluating the effect of anti-nausea drugs in IDO enzyme gene expression and preventing postoperative vomiting and nausea in patients undergoing general anesthesia: A Meta-analysis.
Topics: Anesthesia, General; Antiemetics; Gene Expression; Humans; Isoquinolines; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Randomized Controlled Trials as Topic | 2022 |
147 trial(s) available for quinuclidines and palonosetron
| Article | Year |
|---|---|
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Nausea; Ondansetron; Palonosetron; Quinuclidines; Vomiting | 2003 |
Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Indoles; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Neoplasms; Palonosetron; Quinolizines; Quinuclidines; Severity of Illness Index; Treatment Outcome; Vomiting | 2003 |
Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Injections, Intravenous; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2004 |
Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects.
Topics: Adult; Area Under Curve; Asian People; Constipation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Headache; Humans; Inactivation, Metabolic; Infusions, Intravenous; Injections, Intravenous; Isoquinolines; Liver; Men; Palonosetron; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Time Factors; United States | 2004 |
Palonosetron.
Topics: Antiemetics; Antineoplastic Agents; Humans; Injections, Intravenous; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2004 |
Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers.
Topics: Adult; Antiemetics; Area Under Curve; Feces; Female; Half-Life; Humans; Injections, Intravenous; Isoquinolines; Male; Metabolic Clearance Rate; Palonosetron; Quinuclidines | 2004 |
Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects.
Topics: Adult; Antiemetics; Area Under Curve; Double-Blind Method; Female; Half-Life; Humans; Injections, Intravenous; Isoquinolines; Male; Metabolic Clearance Rate; Palonosetron; Quinuclidines | 2005 |
Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiemetics; Aprepitant; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Isoquinolines; Male; Morpholines; Palonosetron; Quinuclidines | 2005 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Ondansetron; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2006 |
Pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects.
Topics: Adolescent; Adult; Area Under Curve; Biological Availability; Cross-Over Studies; Female; Half-Life; Headache; Humans; Infusions, Intravenous; Isoquinolines; Male; Metabolic Clearance Rate; Middle Aged; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Time Factors | 2006 |
Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2006 |
Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Palonosetron; Quinuclidines; Serotonin Antagonists; Severity of Illness Index; Time Factors; Treatment Outcome; Vomiting | 2006 |
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Benzodiazepines; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Olanzapine; Outcome Assessment, Health Care; Palonosetron; Quinuclidines; United States; Vomiting | 2007 |
Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Isoquinolines; Male; Nausea; Neoplasms, Germ Cell and Embryonal; Palonosetron; Quinuclidines; United States; Vomiting | 2007 |
Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Topics: Acute Disease; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Humans; Isoquinolines; Morpholines; Nausea; Palonosetron; Pilot Projects; Quinuclidines; Vomiting | 2008 |
A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Breast; Double-Blind Method; Female; Gynecologic Surgical Procedures; Humans; Injections, Intravenous; Isoquinolines; Middle Aged; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Serotonin Antagonists; Treatment Failure | 2008 |
A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Breast; Double-Blind Method; Female; Gynecologic Surgical Procedures; Humans; Isoquinolines; Middle Aged; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Serotonin Antagonists | 2008 |
Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children.
Topics: Antineoplastic Agents; Child; Female; Humans; Isoquinolines; Male; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2008 |
Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: c
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial.
Topics: Adult; Antiemetics; Antineoplastic Agents; Asian People; China; Double-Blind Method; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents, Hormonal; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Hematologic Neoplasms; Humans; Isoquinolines; Italy; Male; Middle Aged; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Vomiting; Young Adult | 2009 |
Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Time Factors; Vomiting | 2009 |
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Topics: Adult; Antiemetics; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results.
Topics: Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Eating; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Area Under Curve; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Vomiting; Young Adult | 2009 |
A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cyclophosphamide; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Vomiting | 2009 |
Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Asian People; China; Cross-Over Studies; Double-Blind Method; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Survival Rate; Treatment Outcome; Vomiting; Young Adult | 2011 |
Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Child; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Isoquinolines; Maximum Tolerated Dose; Middle Aged; Nausea; Palonosetron; Placebos; Prognosis; Prospective Studies; Quinuclidines; Serotonin Antagonists; Survival Rate; Vomiting; Young Adult | 2010 |
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glioblastoma; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Temozolomide; Vomiting | 2011 |
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.
Topics: Aged; Anthracyclines; Antineoplastic Agents, Hormonal; Chi-Square Distribution; Confidence Intervals; Dexamethasone; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Health Status Indicators; Humans; Isoquinolines; Male; Middle Aged; Multivariate Analysis; Nausea; Palonosetron; Quinuclidines; Risk Assessment; Serotonin Antagonists; Time Factors; Vomiting | 2011 |
Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Ondansetron; Palonosetron; Quinuclidines; Vomiting | 2011 |
Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano p
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Glucocorticoids; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting; Young Adult | 2011 |
Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dexamethasone; Double-Blind Method; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Melphalan; Middle Aged; Multiple Myeloma; Nausea; Palonosetron; Quinuclidines; Vomiting | 2011 |
Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
Topics: Acute Disease; Adult; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Dexamethasone; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; Isoquinolines; Male; Middle Aged; Nausea; Ondansetron; Palonosetron; Quinuclidines; Serotonin Antagonists; Time Factors; Vomiting | 2010 |
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Isoquinolines; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Ondansetron; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2010 |
Different doses of palonosetron for the prevention of postoperative nausea and vomiting in children undergoing strabismus surgery.
Topics: Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoquinolines; Male; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Random Allocation; Serotonin Antagonists; Severity of Illness Index; Strabismus | 2011 |
A randomized double blind study to evaluate efficacy of palonosetron with dexamethasone versus palonosetron alone for prevention of postoperative and postdischarge nausea and vomiting in subjects undergoing laparoscopic surgeries with high emetogenic risk
Topics: Adult; Anesthesia, General; Antiemetics; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Incidence; Isoquinolines; Laparoscopy; Male; Palonosetron; Postoperative Nausea and Vomiting; Prospective Studies; Quality of Life; Quinuclidines; Risk Factors; Time Factors | 2012 |
A randomized, double-blind trial of palonosetron compared with ondansetron in preventing postoperative nausea and vomiting after gynaecological laparoscopic surgery.
Topics: Adult; Anesthesia; Antiemetics; Demography; Double-Blind Method; Female; Gynecologic Surgical Procedures; Humans; Incidence; Injections, Intravenous; Isoquinolines; Laparoscopy; Ondansetron; Palonosetron; Patient Satisfaction; Postoperative Nausea and Vomiting; Quinuclidines; Treatment Outcome | 2011 |
Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Databases, Factual; Female; Follow-Up Studies; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Time Factors; Vomiting | 2011 |
Electrocardiographic findings of palonosetron in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Blood Pressure; Electrocardiography; Female; Heart Rate; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Time Factors; Vomiting; Young Adult | 2012 |
A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting | 2012 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Melphalan; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Transplantation, Autologous; Treatment Outcome; Vomiting | 2011 |
Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Palonosetron; Pilot Projects; Quinuclidines; Vomiting | 2012 |
A randomized controlled trial of two different interventions for the prevention of postoperative nausea and vomiting: total intravenous anaesthesia using propofol and remifentanil versus prophylactic palonosetron with inhalational anaesthesia using sevofl
Topics: Adult; Anesthetics, Combined; Anesthetics, Inhalation; Anesthetics, Intravenous; Antiemetics; Female; Gynecologic Surgical Procedures; Humans; Isoquinolines; Laparoscopy; Methyl Ethers; Middle Aged; Nitrous Oxide; Palonosetron; Piperidines; Postoperative Nausea and Vomiting; Propofol; Quinuclidines; Remifentanil; Sevoflurane | 2011 |
Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Constipation; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Headache; Hiccup; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Palonosetron; Prospective Studies; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting; Young Adult | 2013 |
Comparison of palanosetron, granisetron and ondansetron as anti-emetics for prevention of postoperative nausea and vomiting in patients undergoing middle ear surgery.
Topics: Adult; Antiemetics; Ear, Middle; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists | 2011 |
Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Child; Child, Preschool; Denmark; Female; Humans; Isoquinolines; Male; Methotrexate; Nausea; Palonosetron; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quinuclidines; Serotonin Antagonists; Time Factors; Vomiting | 2012 |
Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Interleukin-2; Isoquinolines; Male; Melanoma; Middle Aged; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2012 |
Anti-emetic effect of ondansetron and palonosetron in thyroidectomy: a prospective, randomized, double-blind study.
Topics: Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans; Isoquinolines; Middle Aged; Ondansetron; Pain Measurement; Pain, Postoperative; Palonosetron; Postoperative Care; Postoperative Nausea and Vomiting; Quinuclidines; Thyroidectomy; Treatment Outcome; Young Adult | 2012 |
Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2012 |
Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC).
Topics: Aged; Antiemetics; Antineoplastic Agents; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Patient Safety; Pilot Projects; Quinuclidines; Salvage Therapy; Treatment Outcome; Vomiting | 2012 |
Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Isoquinolines; Male; Middle Aged; Nausea; Ondansetron; Organoplatinum Compounds; Oxaliplatin; Palonosetron; Quinuclidines; Retrospective Studies; Treatment Outcome | 2012 |
Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Granisetron; Humans; Intention to Treat Analysis; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Prochlorperazine; Quinuclidines; Serotonin Antagonists | 2012 |
[Evaluation of palonosetron for the prevention of nausea and vomiting induced by colon cancer chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2012 |
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Female; Humans; Isoquinolines; Male; Metoclopramide; Middle Aged; Morpholines; Nausea; Neoplasms; Olanzapine; Palonosetron; Quinuclidines; Vomiting | 2013 |
Effect of palonosetron on postanesthetic shivering after propofol-remifentanil total intravenous anesthesia.
Topics: Anesthesia Recovery Period; Anesthesia, Intravenous; Body Temperature; Double-Blind Method; Female; Humans; Isoquinolines; Laparoscopy; Middle Aged; Palonosetron; Piperidines; Postoperative Complications; Propofol; Prospective Studies; Quinuclidines; Remifentanil; Shivering | 2013 |
Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2013 |
Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis.
Topics: Age Factors; Antiemetics; Antineoplastic Agents; Female; Humans; Isoquinolines; Male; Middle Aged; Multivariate Analysis; Nausea; Palonosetron; Precision Medicine; Quinuclidines; Risk Factors; Sex Factors; Smoking; Vomiting | 2013 |
The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Treatment Outcome; Vomiting | 2013 |
A combination of aprepitant, palonosetron, and dexamethasone prevents emesis associated with anthracycline-containing regimens for patients with breast cancer. A retrospective study.
Topics: Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Dexamethasone; Female; Granisetron; Humans; Isoquinolines; Middle Aged; Morpholines; Palonosetron; Quinuclidines; Retrospective Studies; Treatment Outcome; Vomiting | 2015 |
Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Constipation; Dexamethasone; Doxorubicin; Female; Headache; Humans; Isoquinolines; Middle Aged; Nausea; Paclitaxel; Palonosetron; Quinuclidines; Serotonin Antagonists; Time Factors; Treatment Outcome; Vomiting; Young Adult | 2013 |
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Ondansetron; Palonosetron; Pilot Projects; Prospective Studies; Quinuclidines; Vomiting | 2013 |
Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoprevention; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2014 |
Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin-a phase II study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Isoquinolines; Middle Aged; Nausea; Palonosetron; Prednisolone; Quinuclidines; Vaginal Neoplasms; Vomiting; Vulvar Neoplasms | 2013 |
Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2013 |
Netupitant PET imaging and ADME studies in humans.
Topics: Adult; Area Under Curve; Bile; Biomarkers; Drug Combinations; Humans; Isoquinolines; Kidney; Liver; Male; Middle Aged; Neurokinin-1 Receptor Antagonists; Palonosetron; Piperidines; Positron-Emission Tomography; Pyridines; Quinuclidines; Radiopharmaceuticals; Serotonin 5-HT3 Receptor Antagonists; Tetrazoles; Tissue Distribution; Young Adult | 2014 |
Effect of palonosetron on the QTc interval in patients undergoing sevoflurane anaesthesia.
Topics: Adult; Aged; Anesthesia, Inhalation; Anesthetics, Inhalation; Antiemetics; Blood Pressure; Double-Blind Method; Electrocardiography; Electrolytes; Female; Heart Rate; Humans; Isoquinolines; Long QT Syndrome; Male; Methyl Ethers; Middle Aged; Monitoring, Intraoperative; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Sevoflurane; Treatment Outcome; Young Adult | 2014 |
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Granisetron; Humans; Indoles; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2014 |
Efficacy of palonosetron for the prevention of postoperative nausea and vomiting: a randomized, double-blinded, placebo-controlled trial.
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Female; Follow-Up Studies; Humans; Isoquinolines; Male; Middle Aged; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Risk Assessment; Sample Size; Surgical Procedures, Operative; Treatment Outcome; Young Adult | 2014 |
Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Surveys and Questionnaires; Vomiting | 2014 |
Comparison of palonosetron with palonosetron-dexamethasone combination for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy.
Topics: Adult; Anesthesia; Antiemetics; Cholecystectomy, Laparoscopic; Dexamethasone; Double-Blind Method; Drug Combinations; Female; Humans; Isoquinolines; Male; Middle Aged; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Young Adult | 2014 |
Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dexamethasone; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vomiting; Young Adult | 2014 |
Efficacy of palonosetron versus ramosetron on preventing opioid-based analgesia-related nausea and vomiting after lumbar spinal surgery: a prospective, randomized, and double-blind trial.
Topics: Adult; Aged; Analgesics, Opioid; Antiemetics; Benzimidazoles; Double-Blind Method; Female; Humans; Isoquinolines; Lumbar Vertebrae; Male; Middle Aged; Orthopedic Procedures; Pain Management; Palonosetron; Postoperative Nausea and Vomiting; Prospective Studies; Quinuclidines; Treatment Outcome | 2014 |
Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy.
Topics: Administration, Intravenous; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Injections, Subcutaneous; Isoquinolines; Male; Middle Aged; Neoplasms; Palonosetron; Platinum; Quinuclidines; Treatment Outcome; Vomiting | 2014 |
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Drug Combinations; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2014 |
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.
Topics: Administration, Oral; Antineoplastic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2014 |
A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
Topics: Antineoplastic Agents; Double-Blind Method; Drug Combinations; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2014 |
Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Female; Humans; Isoquinolines; Male; Morpholines; Nausea; Neoplasms, Germ Cell and Embryonal; Palonosetron; Quinuclidines; Testicular Neoplasms; Vomiting | 2014 |
Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Neoplasms; Palonosetron; Prospective Studies; Quality of Life; Quinuclidines; Vomiting | 2014 |
Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Doxorubicin; Electric Stimulation Therapy; Epirubicin; Humans; Ifosfamide; Isoquinolines; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting; Young Adult | 2014 |
Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2014 |
A prospective, randomized, double-blind, multicenter trial to evaluate the therapeutic efficacy and safety of palonosetron in the treatment of postoperative nausea and vomiting over a 72-h period.
Topics: Administration, Intravenous; Adult; Anesthesia, General; Antiemetics; Double-Blind Method; Female; Humans; Incidence; Isoquinolines; Male; Middle Aged; Palonosetron; Postoperative Nausea and Vomiting; Prospective Studies; Quinuclidines; Risk Factors | 2015 |
Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Carboplatin; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Japan; Lung Neoplasms; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Salvage Therapy; Surveys and Questionnaires; Treatment Outcome; Vomiting | 2015 |
Palonosetron versus ondansetron as rescue medication for postoperative nausea and vomiting: a randomized, multicenter, open-label study.
Topics: Adult; Antiemetics; Female; Humans; Isoquinolines; Male; Middle Aged; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines | 2014 |
The Efficacy of Palonosetron Plus Dexamethasone in Preventing Chemoradiotherapy-induced Nausea and Emesis in Patients Receiving Daily Low-dose Cisplatin-based Concurrent Chemoradiotherapy for Uterine Cervical Cancer: A Phase II Study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Middle Aged; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Treatment Outcome; Uterine Cervical Neoplasms; Vomiting | 2017 |
Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomised trial.
Topics: Adult; Analgesia, Patient-Controlled; Antiemetics; Aprepitant; Double-Blind Method; Female; Gynecologic Surgical Procedures; Humans; Isoquinolines; Laparoscopy; Middle Aged; Morpholines; Pain Measurement; Pain, Postoperative; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Young Adult | 2014 |
Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, do
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Double-Blind Method; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Prospective Studies; Quinuclidines; Severity of Illness Index; Treatment Outcome; Vomiting | 2015 |
Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomas.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carcinoma; Cisplatin; Dexamethasone; Drug Therapy, Combination; Eating; Female; Head and Neck Neoplasms; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Quinuclidines; Serotonin Antagonists | 2014 |
Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-da
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Bone Neoplasms; Cross-Over Studies; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Quinuclidines; Sarcoma; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting; Young Adult | 2015 |
Aprepitant as prophylaxis of chemotherapy-induced nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for adjuvant breast cancer.
Topics: Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dexamethasone; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2015 |
Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemothe
Topics: Administration, Intravenous; Administration, Oral; Antiemetics; Cisplatin; Dexamethasone; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2015 |
Efficacy of palonosetron and ramosetron on postoperative nausea and vomiting related to intravenous patient-controlled analgesia with opioids after gynecological laparoscopic surgery (double-blinded prospective randomized controlled trial).
Topics: Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Antiemetics; Benzimidazoles; Double-Blind Method; Female; Fentanyl; Gynecologic Surgical Procedures; Humans; Isoquinolines; Laparoscopy; Middle Aged; Pain, Postoperative; Palonosetron; Postoperative Nausea and Vomiting; Prospective Studies; Quinuclidines | 2015 |
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
Topics: Activities of Daily Living; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Isoquinolines; Italy; Male; Metoclopramide; Middle Aged; Morpholines; Nausea; Palonosetron; Quality of Life; Quinuclidines; Risk Factors; Time Factors; Treatment Outcome; Vomiting; Young Adult | 2015 |
Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study.
Topics: Aged; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Patient Preference; Prospective Studies; Quinuclidines; Single-Blind Method; Treatment Outcome; Vomiting | 2015 |
Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dexamethasone; Female; Humans; Irinotecan; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palonosetron; Quality of Life; Quinuclidines; Serotonin Antagonists; Treatment Outcome | 2015 |
Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Carboplatin; Constipation; Dexamethasone; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Middle Aged; Nausea; Paclitaxel; Palonosetron; Quinuclidines; Serotonin Antagonists; Sleep Initiation and Maintenance Disorders; Vomiting | 2015 |
Implications of palonosetron in elderly patients undergoing laparoscopic cholecystectomy with respect to its anti-shivering effect.
Topics: Aged; Aged, 80 and over; Anesthesia; Cholecystectomy, Laparoscopic; Female; Humans; Hypothermia; Isoquinolines; Male; Monitoring, Intraoperative; Pain, Postoperative; Palonosetron; Preoperative Care; Quinuclidines; Serotonin Antagonists; Shivering; Treatment Outcome | 2016 |
Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers.
Topics: Administration, Intravenous; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Isoquinolines; Male; Middle Aged; Palonosetron; Quinuclidines; Reference Values; Serotonin Antagonists | 2016 |
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benzodiazepines; Cisplatin; Dexamethasone; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Olanzapine; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Vomiting | 2016 |
Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Cross-Over Studies; Diet; Drug Administration Schedule; Female; Genital Neoplasms, Female; Granisetron; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Paclitaxel; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2015 |
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: A randomized, multicenter, phase-II trial.
Topics: Aged; Antiemetics; Antineoplastic Agents; Carboplatin; Dexamethasone; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Middle Aged; Nausea; Paclitaxel; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2015 |
Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
Topics: Administration, Cutaneous; Adult; Aged; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Double-Blind Method; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Patient Satisfaction; Quinuclidines; Remission Induction; Serotonin Antagonists; Vomiting | 2016 |
Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2015 |
Comparison of palonosetron, granisetron, and ramosetron for the prevention of postoperative nausea and vomiting after laparoscopic gynecologic surgery: a prospective randomized trial.
Topics: Adult; Aged; Benzimidazoles; Double-Blind Method; Female; Granisetron; Gynecologic Surgical Procedures; Humans; Isoquinolines; Laparoscopy; Middle Aged; Palonosetron; Postoperative Nausea and Vomiting; Prospective Studies; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists | 2015 |
Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Agents; Aprepitant; Breast Neoplasms; Dexamethasone; Female; Humans; Isoquinolines; Japan; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Vomiting | 2016 |
Evaluation of weight-adjusted doses of palonosetron for prevention of postoperative nausea and vomiting in day care laparoscopic gynaecological surgery: A dose ranging, randomised controlled trial.
Topics: Administration, Intravenous; Adult; Ambulatory Surgical Procedures; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Dosage Calculations; Female; Gynecologic Surgical Procedures; Humans; India; Isoquinolines; Laparoscopy; Middle Aged; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Serotonin Antagonists; Tertiary Care Centers; Time Factors; Treatment Outcome; Young Adult | 2016 |
Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Odds Ratio; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2015 |
Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Infant; Internationality; Isoquinolines; Male; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2016 |
Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Isoquinolines; Middle Aged; Nausea; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2016 |
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Dexamethasone; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Uterine Cervical Neoplasms; Vomiting | 2016 |
A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Olanzapine; Palonosetron; Quinuclidines; Vomiting | 2016 |
Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens.
Topics: Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Vomiting | 2016 |
Aprepitant, granisetron, and dexamethasone versus palonosetron and dexamethasone for prophylaxis of cisplatin-induced nausea and vomiting in patients with upper gastrointestinal cancer: a randomized crossover phase II trial (KDOG 1002).
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Cross-Over Studies; Dexamethasone; Esophageal Neoplasms; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Stomach Neoplasms; Vomiting | 2016 |
Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).
Topics: Administration, Intravenous; Antineoplastic Agents; Chemoradiotherapy; Dacarbazine; Female; Glioma; Humans; Isoquinolines; Male; Middle Aged; Palonosetron; Quality of Life; Quinuclidines; Surveys and Questionnaires; Temozolomide | 2016 |
Efficacy of palonosetron plus aprepitant in preventing chemoradiotherapy-induced nausea and emesis in patients receiving daily low-dose cisplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a phase II study.
Topics: Adult; Aged; Aprepitant; Chemoradiotherapy; Cisplatin; Drug Therapy, Combination; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Uterine Cervical Neoplasms; Vomiting | 2016 |
Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Palonosetron; Pyridines; Quinuclidines; Receptors, Neurokinin-1 | 2016 |
Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2016 |
Comparison of Ramosetron and Palonosetron for Preventing Nausea and Vomiting after Spinal Surgery: Association With ABCB1 Polymorphisms.
Topics: Adult; Aged; Aged, 80 and over; Analgesia, Patient-Controlled; Analgesics, Opioid; Antiemetics; ATP Binding Cassette Transporter, Subfamily B; Benzimidazoles; Double-Blind Method; Female; Fentanyl; Genotype; Humans; Incidence; Isoquinolines; Male; Middle Aged; Pain, Postoperative; Palonosetron; Polymorphism, Genetic; Postoperative Nausea and Vomiting; Prospective Studies; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Spine; Young Adult | 2017 |
Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Olanzapine; Organoplatinum Compounds; Palonosetron; Quality of Life; Quinuclidines; Vomiting | 2017 |
A prospective study of the antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Isoquinolines; Japan; Lymphoma; Male; Middle Aged; Nausea; Palonosetron; Prednisolone; Prospective Studies; Quinuclidines; Serotonin Antagonists; Vincristine; Vomiting; Young Adult | 2016 |
Comparison of the Prophylactic Antiemetic Efficacy of Aprepitant Plus Palonosetron Versus Aprepitant Plus Ramosetron in Patients at High Risk for Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy: A Prospective Randomized-controlled Tri
Topics: Adolescent; Adult; Aged; Antiemetics; Aprepitant; Benzimidazoles; Cholecystectomy, Laparoscopic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Palonosetron; Postoperative Nausea and Vomiting; Prospective Studies; Quinuclidines; Treatment Outcome; Young Adult | 2016 |
A randomized, double-blind trial evaluating the efficacy of palonosetron with total intravenous anesthesia using propofol and remifentanil for the prevention of postoperative nausea and vomiting after gynecologic surgery.
Topics: Adult; Anesthesia, General; Anesthesia, Intravenous; Antiemetics; Double-Blind Method; Female; Gynecologic Surgical Procedures; Humans; Incidence; Isoquinolines; Laparoscopy; Middle Aged; Palonosetron; Patient Satisfaction; Piperidines; Postoperative Nausea and Vomiting; Propofol; Prospective Studies; Quinuclidines; Remifentanil | 2016 |
Palonosetron and hydroxyzine pre-treatment reduces the objective signs of experimentally-induced acute opioid withdrawal in humans: a double-blinded, randomized, placebo-controlled crossover study.
Topics: Cross-Over Studies; Double-Blind Method; Drug Synergism; Healthy Volunteers; Humans; Hydroxyzine; Isoquinolines; Male; Morphine; Naloxone; Palonosetron; Quinuclidines; Substance Withdrawal Syndrome; Young Adult | 2017 |
A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Drug-Related Side Effects and Adverse Reactions; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Middle Aged; Nausea; Olanzapine; Ondansetron; Palonosetron; Prospective Studies; Quinuclidines; Transplantation Conditioning; Treatment Outcome; Vomiting; Young Adult | 2017 |
Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study.
Topics: Adult; Aged; Antiemetics; Aprepitant; Dexamethasone; Drug Therapy, Combination; Humans; Isoquinolines; Melphalan; Middle Aged; Morpholines; Multiple Myeloma; Myeloablative Agonists; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Transplantation, Autologous; Treatment Outcome | 2017 |
NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.
Topics: Adult; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Pyridines; Quinuclidines; Vomiting; Young Adult | 2017 |
Effect of transcutaneous electrical acupoint stimulation combined with palonosetron on chemotherapy-induced nausea and vomiting: a single-blind, randomized, controlled trial.
Topics: Acupuncture Points; Adult; Aged; Chemoembolization, Therapeutic; Cisplatin; Combined Modality Therapy; Female; Humans; Isoquinolines; Liver Neoplasms; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Severity of Illness Index; Single-Blind Method; Transcutaneous Electric Nerve Stimulation; Treatment Outcome; Vomiting | 2017 |
Higher dose of palonosetron versus lower dose of palonosetron plus droperidol to prevent postoperative nausea and vomiting after eye enucleation and orbital hydroxyapatite implant surgery: a randomized, double-blind trial.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Antiemetics; Dose-Response Relationship, Drug; Double-Blind Method; Droperidol; Durapatite; Eye Enucleation; Female; Humans; Incidence; Isoquinolines; Male; Middle Aged; Orbital Implants; Palonosetron; Postoperative Nausea and Vomiting; Prospective Studies; Prosthesis Implantation; Quinuclidines; Young Adult | 2017 |
Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Humans; Infant; Infant, Newborn; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2017 |
A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Olanzapine; Palonosetron; Quinuclidines; Thoracic Neoplasms; Vomiting | 2017 |
A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Isoquinolines; Lymphoma; Male; Middle Aged; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Treatment Outcome; Vomiting | 2018 |
Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Epirubicin; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Thalidomide; Vomiting; Young Adult | 2017 |
Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dexamethasone; Double-Blind Method; Female; Humans; Infant; Infant, Newborn; Isoquinolines; Male; Nausea; Neoplasms; Ondansetron; Palonosetron; Prospective Studies; Quinuclidines; Vomiting | 2018 |
A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Drug Therapy, Combination; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Outcome Assessment, Health Care; Paclitaxel; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2017 |
A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Dexamethasone; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Neoplasms; Olanzapine; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2018 |
Palonosetron Prevents Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Oral Cancer Patients.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Mouth Neoplasms; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2017 |
Effects of palonosetron for prophylaxis of postoperative nausea and vomiting in high-risk patients undergoing total knee arthroplasty: A prospective, randomized, double-blind, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Analgesia, Patient-Controlled; Analgesics, Opioid; Antiemetics; Arthroplasty, Replacement, Knee; Double-Blind Method; Female; Fentanyl; Humans; Isoquinolines; Middle Aged; Pain, Postoperative; Palonosetron; Postoperative Nausea and Vomiting; Prospective Studies; Quinuclidines; Risk Factors | 2018 |
Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studie
Topics: Administration, Oral; Anthracyclines; Antiemetics; Aprepitant; Cyclophosphamide; Dexamethasone; Double-Blind Method; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoquinolines; Male; Middle Aged; Palonosetron; Pyridines; Quinuclidines; Treatment Outcome | 2019 |
Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial.
Topics: Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Humans; Male; Metoclopramide; Nausea; Palonosetron; Quality of Life; Quinuclidines; Vomiting | 2021 |
[Efficacy of Antiemetic Therapy with Aprepitant, Palonosetron, and Dexamethasone in Patients Receiving Oxaliplatin-Based Chemotherapy].
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Humans; Japan; Oxaliplatin; Palonosetron; Quinuclidines; Vomiting | 2020 |
Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial.
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Drug Combinations; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Pilot Projects; Pyridines; Quinuclidines; Vomiting | 2021 |
Phase III study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients.
Topics: Antiemetics; Antineoplastic Agents; Child; Dexamethasone; Double-Blind Method; Humans; Infant, Newborn; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2021 |
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Humans; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2021 |
A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
Topics: Antibiotics, Antineoplastic; Antiemetics; Antineoplastic Agents; Aprepitant; Double-Blind Method; Humans; Isoquinolines; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Vomiting | 2021 |
Does a single dose of palonosetron have any role in preventing acute chemotherapy-induced nausea and vomiting in pediatric osteosarcoma patients without dexamethasone? A randomized clinical trial.
Topics: Antineoplastic Agents; Child; Dexamethasone; Humans; Isoquinolines; Nausea; Osteosarcoma; Palonosetron; Quinuclidines; Vomiting | 2022 |
Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study.
Topics: Antiemetics; Antineoplastic Agents; Benzeneacetamides; Cisplatin; Dexamethasone; Humans; Nausea; Palonosetron; Piperazines; Pyridines; Quinuclidines; Vomiting | 2022 |
Efficacy of the dexamethasone-sparing triplet regimen for preventing cisplatin-induced emesis: a combined analysis.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Isoquinolines; Palonosetron; Quinuclidines; Vomiting | 2022 |
123 other study(ies) available for quinuclidines and palonosetron
| Article | Year |
|---|---|
The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro.
Topics: Animals; Autoradiography; Binding, Competitive; Brain; Guinea Pigs; Ileum; In Vitro Techniques; Isoquinolines; Mice; Muscle Contraction; Muscle, Smooth; Myenteric Plexus; Palonosetron; Quinuclidines; Quipazine; Radioligand Assay; Rats; Receptors, Serotonin; Serotonin Antagonists; Stereoisomerism; Structure-Activity Relationship | 1995 |
Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo.
Topics: Administration, Oral; Animals; Bradycardia; Dogs; Dose-Response Relationship, Drug; Duodenum; Female; Ferrets; Granisetron; Hemodynamics; Injections, Intravenous; Injections, Subcutaneous; Isoquinolines; Male; Ondansetron; Palonosetron; Quinuclidines; Random Allocation; Rats; Serotonin; Serotonin Antagonists; Stereoisomerism; Vomiting | 1995 |
2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists.
Topics: Animals; Cisplatin; Computer Simulation; Dogs; Ferrets; Isoquinolines; Male; Models, Molecular; Molecular Structure; Palonosetron; Pyridones; Quinuclidines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin Antagonists; Stereoisomerism; Structure-Activity Relationship; Vomiting | 1993 |
Palonosetron. RS 25259, RS 25259 197.
Topics: Animals; Antiemetics; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Guinea Pigs; Humans; Isoquinolines; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Rats; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Serotonin Antagonists; Vomiting | 1999 |
Palonosetron (Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Receptors, Serotonin; Vomiting | 2004 |
Physical and chemical stability of palonosetron HCl in 4 infusion solutions.
Topics: Antiemetics; Drug Incompatibility; Drug Stability; Drug Storage; Glucose; Infusions, Intravenous; Isoquinolines; Isotonic Solutions; Palonosetron; Pharmaceutical Solutions; Quinuclidines; Ringer's Lactate; Sodium Chloride | 2004 |
Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration.
Topics: Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Docetaxel; Drug Combinations; Drug Stability; Injections, Intravenous; Isoquinolines; Paclitaxel; Palonosetron; Quinuclidines; Serotonin Antagonists; Taxoids | 2004 |
New drugs 04. Part III.
Topics: Adrenergic alpha-Antagonists; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiemetics; Antineoplastic Agents; Aprepitant; Boronic Acids; Bortezomib; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Glucans; Glucose; Glucosylceramidase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Icodextrin; Immunosuppressive Agents; Isoquinolines; Morpholines; Nurse's Role; Omalizumab; Palonosetron; Patient Education as Topic; Pyrazines; Pyrimidines; Quinazolines; Quinuclidines; Rosuvastatin Calcium; Sulfonamides | 2004 |
Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration.
Topics: Drug Interactions; Drug Stability; Epirubicin; Isoquinolines; Nephelometry and Turbidimetry; Palonosetron; Quinuclidines | 2005 |
5HT3-receptor antagonists as antiemetics in cancer.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Granisetron; Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Practice Guidelines as Topic; Quinolizines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Tropisetron; Vomiting | 2005 |
Compatibility of palonosetron with cyclophosphamide and with ifosfamide during simulated Y-site administration.
Topics: Antiemetics; Antineoplastic Agents, Alkylating; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Cyclophosphamide; Drug Stability; Glucose; Ifosfamide; Infusions, Intravenous; Isoquinolines; Palonosetron; Pharmaceutical Solutions; Quinuclidines | 2005 |
[Achieving optimal antiemetic management].
Topics: Antiemetics; Clinical Trials as Topic; Drug Administration Schedule; Humans; Infusions, Intravenous; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2005 |
[Second generation of 5-HT3 antagonists].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Humans; Isoquinolines; Male; Neoplasms; Palliative Care; Palonosetron; Quinuclidines; Vomiting | 2005 |
Applying new data to manage CINV: achieving optimal outcomes through a comprehensive care model.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Comprehensive Health Care; Evidence-Based Medicine; Humans; Isoquinolines; Models, Organizational; Morpholines; Nausea; Neoplasms; Nurse's Role; Oncology Nursing; Palonosetron; Patient Care Team; Practice Guidelines as Topic; Quinuclidines; Total Quality Management; Vomiting | 2006 |
Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
Topics: Antiemetics; Granisetron; Humans; Indoles; Isoquinolines; Nausea; Ondansetron; Organoplatinum Compounds; Palonosetron; Quinolizines; Quinuclidines; Treatment Outcome; Vomiting | 2006 |
Enantioseparation of palonosetron hydrochloride by micellar electrokinetic chromatography with sodium cholate as chiral selector.
Topics: Chromatography, Micellar Electrokinetic Capillary; Isoquinolines; Molecular Structure; Palonosetron; Quinuclidines; Reproducibility of Results; Sodium Cholate; Stereoisomerism | 2006 |
Determination of palonosetron in human plasma by liquid chromatography-electrospray ionization-mass spectrometry.
Topics: Adult; Antiemetics; Area Under Curve; Calibration; Chromatography, High Pressure Liquid; Female; Half-Life; Humans; Indicators and Reagents; Isoquinolines; Male; Palonosetron; Quality Control; Quinuclidines; Reproducibility of Results; Solutions; Spectrometry, Mass, Electrospray Ionization | 2007 |
Are all 5-HT3 receptor antagonists the same?
Topics: Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Therapeutic Equivalency; Vomiting | 2007 |
Preventing emesis in lung cancer patients.
Topics: Antiemetics; Antineoplastic Agents; Humans; Isoquinolines; Lung Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Vomiting | 2007 |
Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration.
Topics: Analgesics, Opioid; Antiemetics; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Incompatibility; Drug Stability; Infusions, Intravenous; Isoquinolines; Nephelometry and Turbidimetry; Palonosetron; Particle Size; Pharmaceutical Solutions; Quinuclidines; Receptors, Opioid | 2007 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipation; Diarrhea; Drug Interactions; Dyspepsia; Fatigue; Fever; Granisetron; Headache; Hiccup; Humans; Indoles; Injections, Intravenous; Isoquinolines; Morpholines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Vomiting | 2007 |
Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy.
Topics: Adult; Age Factors; Aged; Antiemetics; Antineoplastic Agents; Austria; Breast Neoplasms; Cancer Care Facilities; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Practice Guidelines as Topic; Product Surveillance, Postmarketing; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Sex Factors; Surveys and Questionnaires; Time Factors; Vomiting | 2008 |
We're tired of waiting.
Topics: Antiemetics; Female; Humans; Isoquinolines; Male; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Risk Factors; Serotonin Antagonists | 2008 |
Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor.
Topics: Animals; Antiemetics; Binding Sites; Calcium; Cell Line; Granisetron; Isoquinolines; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Radioligand Assay; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Transfection | 2008 |
Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration.
Topics: Antiemetics; Atropine; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Incompatibility; Drug Stability; Famotidine; Heparin; Infusions, Intravenous; Isoquinolines; Lidocaine; Nephelometry and Turbidimetry; Palonosetron; Pharmaceutical Solutions; Potassium Chloride; Quinuclidines; Serotonin Antagonists | 2008 |
Palonosetron--a single-dose antiemetic adjunct for hepatic artery radioembolization: a feasibility study.
Topics: Embolization, Therapeutic; Feasibility Studies; Female; Hepatic Artery; Humans; Isoquinolines; Liver Neoplasms; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Treatment Outcome; Vomiting; Yttrium Radioisotopes | 2009 |
Effect of 5-HT3 antagonists and a 5-HT(1A) agonist on fluoxetine-induced conditioned gaping reactions in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiemetics; Autoreceptors; Conditioning, Psychological; Dose-Response Relationship, Drug; Fluoxetine; Isoquinolines; Lithium Chloride; Male; Nausea; Ondansetron; Palonosetron; Quinuclidines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists | 2009 |
Seizure associated with palonosetron.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Isoquinolines; Palonosetron; Quinuclidines; Seizures; Serotonin Antagonists | 2009 |
Palonosetron: more than just another option?
Topics: Clinical Trials as Topic; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus).
Topics: Amygdala; Animals; Antiemetics; Antineoplastic Agents; Area Postrema; Brain; Cisplatin; Disease Models, Animal; Female; Isoquinolines; Mesencephalon; Palonosetron; Proto-Oncogene Proteins c-fos; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Shrews; Solitary Nucleus; Time Factors; Vomiting | 2009 |
[Postoperative nausea and vomiting--what's new in anti-emetic pharmacotherapy?].
Topics: Antiemetics; Aprepitant; Humans; Isoquinolines; Morpholines; Neurokinin-1 Receptor Antagonists; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Serotonin Antagonists; Treatment Outcome | 2009 |
Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Transplantation Conditioning; Transplantation, Autologous; Vomiting | 2010 |
Enantioseparation of palonosetron hydrochloride by capillary zone electrophoresis with high-concentration beta-CD as chiral selector.
Topics: beta-Cyclodextrins; Electrophoresis, Capillary; Isoquinolines; Palonosetron; Quinuclidines; Stereoisomerism | 2009 |
Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function.
Topics: Animals; Cell Line; Cell Membrane; Cell-Free System; Granisetron; Humans; Isoquinolines; Isotope Labeling; Microscopy, Fluorescence; Palonosetron; Protein Transport; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Substrate Specificity; Time Factors; Tritium | 2010 |
Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.
Topics: Antineoplastic Agents; Carmustine; Emetics; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymphoma; Nausea; Ondansetron; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2009 |
Palonosetron to prevent nausea and vomiting in children undergoing BMT: efficacy and safety.
Topics: Adolescent; Antiemetics; Bone Marrow Transplantation; Child; Child, Preschool; Female; Humans; Infant; Isoquinolines; Male; Nausea; Neoplasms; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Vomiting | 2010 |
Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Ambulatory Care; Antiemetics; Antineoplastic Agents; Boston; Cisplatin; Drug Administration Schedule; Drug Substitution; Emergency Service, Hospital; Fallopian Tube Neoplasms; Female; Health Resources; Humans; Isoquinolines; Length of Stay; Middle Aged; Nausea; Ondansetron; Ovarian Neoplasms; Palonosetron; Patient Readmission; Premedication; Quinuclidines; Risk Assessment; Risk Factors; Serotonin Antagonists; Time Factors; Treatment Outcome; Vomiting | 2011 |
Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Health Status Indicators; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Prospective Studies; Quality of Life; Quinuclidines; Serotonin Antagonists; Surveys and Questionnaires; Vomiting; Young Adult | 2011 |
Palonosetron induced anaphylaxis in an adult female.
Topics: Adult; Anaphylaxis; Breast Neoplasms; Female; Humans; Isoquinolines; Nausea; Neoplasm Recurrence, Local; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2010 |
The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.
Topics: Action Potentials; Animals; Antiemetics; Antineoplastic Agents; Calcium; Cell Line; Cisplatin; Disease Models, Animal; Dose-Response Relationship, Drug; Isoquinolines; Male; Neurokinin-1 Receptor Antagonists; Neurons; Nodose Ganglion; Palonosetron; Quinuclidines; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-1; Receptors, Serotonin, 5-HT3; Serotonin; Serotonin 5-HT3 Receptor Antagonists; Substance P; Vomiting | 2010 |
Palonosetron-induced migraine-type headache.
Topics: Adult; Anesthesia; Antiemetics; Female; Humans; Isoquinolines; Laparoscopy; Migraine Disorders; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Serotonin Antagonists; Severity of Illness Index | 2011 |
Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Carboplatin; Cisplatin; Cohort Studies; Cyclophosphamide; Databases, Factual; Female; Follow-Up Studies; Hospitalization; Humans; Isoquinolines; Logistic Models; Lung Neoplasms; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting | 2012 |
Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Isoquinolines; Male; Middle Aged; Nausea; Outpatients; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; United States; Vomiting; Young Adult | 2011 |
Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Topics: Adolescent; Aged; Antiemetics; Antineoplastic Agents; Databases, Factual; Female; Follow-Up Studies; Humans; Isoquinolines; Male; Middle Aged; Multivariate Analysis; Nausea; Neoplasms; Outpatient Clinics, Hospital; Palonosetron; Quinuclidines; Regression Analysis; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Vomiting; Young Adult | 2011 |
Determination of palonosetron in human urine by LC-MS/MS.
Topics: Chromatography, Liquid; Humans; Isoquinolines; Palonosetron; Quinuclidines; Sensitivity and Specificity; Tandem Mass Spectrometry | 2011 |
Development and validation of a stability-indicating LC method for determining palonosetron hydrochloride, its related compounds and degradation products using naphthalethyl stationary phase.
Topics: Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Stability; Hydrogen-Ion Concentration; Isoquinolines; Molecular Structure; Naphthalenes; Palonosetron; Photolysis; Quinuclidines; Reference Standards; Reproducibility of Results; Serotonin Antagonists; Spectrophotometry, Ultraviolet; Technology, Pharmaceutical; Temperature | 2011 |
Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Topics: Adult; Antiemetics; Antineoplastic Agents; Aprepitant; Databases, Factual; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Logistic Models; Male; Middle Aged; Morpholines; Multivariate Analysis; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2011 |
Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Female; Hodgkin Disease; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vinblastine; Vomiting; Young Adult | 2012 |
Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dexamethasone; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Nausea; Ondansetron; Palonosetron; Quinuclidines; Retrospective Studies; Vomiting | 2012 |
Possible anaphylaxis to palonoestron.
Topics: Adult; Anaphylaxis; Female; Humans; Isoquinolines; Palonosetron; Quinuclidines; Serotonin Antagonists | 2012 |
Serotonin receptor type 3 antagonists improve obesity-associated fatty liver disease in mice.
Topics: Actins; Animals; Azo Compounds; Drug Evaluation, Preclinical; Duodenum; Endotoxins; Fatty Liver; Indoles; Inflammation; Isoquinolines; Leptin; Liver; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Palonosetron; Proteins; Quinuclidines; Serotonin; Serotonin 5-HT3 Receptor Antagonists; Tropisetron; Tumor Necrosis Factor-alpha | 2011 |
Determination of palonosetron in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study.
Topics: Calibration; Chromatography, Liquid; Humans; Isoquinolines; Limit of Detection; Palonosetron; Quinuclidines; Reference Standards; Serotonin Antagonists; Tandem Mass Spectrometry | 2012 |
[The efficacy of aprepitant and palonosetron on cisplatin doublet in lung cancer].
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Vomiting | 2011 |
Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Electrocardiography; Heart Rate; Humans; Isoquinolines; Middle Aged; Nausea; Neoplasms; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Vomiting; Young Adult | 2012 |
Is palonosetron also effective for opioid-induced and post-discharge nausea and vomiting?
Topics: Antiemetics; Female; Humans; Isoquinolines; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Thyroidectomy | 2012 |
Liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry method for the quantitation of palonosetron in human plasma and urine: Application to a pharmacokinetic study.
Topics: Chromatography, Liquid; Drug Stability; Female; Humans; Isoquinolines; Least-Squares Analysis; Male; Palonosetron; Quinuclidines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2012 |
Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects.
Topics: Animals; Cell Line, Tumor; Drug Synergism; Isoquinolines; Neurokinin-1 Receptor Antagonists; Palonosetron; Pyridines; Quinuclidines; Receptors, Neurokinin-1; Serotonin 5-HT3 Receptor Antagonists; Substance P | 2012 |
Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Arrhythmias, Cardiac; Electrocardiography; Female; Heart Rate; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Patient Selection; Predictive Value of Tests; Prospective Studies; Quinuclidines; Risk Assessment; Risk Factors; Serotonin 5-HT3 Receptor Antagonists; Time Factors; Turkey; Vomiting | 2012 |
[Comparison of the effect of palonosetron versus tropisetron in prevention of vomiting in patients receiving high dose cisplatin-based chemotherapy].
Topics: Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Eating; Female; Humans; Indoles; Isoquinolines; Male; Middle Aged; Neoplasms; Palonosetron; Quinuclidines; Tropisetron; Vomiting | 2012 |
Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Carboplatin; Cisplatin; Female; Health Care Surveys; Hospitalization; Humans; Isoquinolines; Logistic Models; Lung Neoplasms; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2012 |
[Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Isoquinolines; Leucovorin; Male; Middle Aged; Nausea; Organoplatinum Compounds; Palonosetron; Quinuclidines; Retrospective Studies; Vomiting | 2012 |
Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
Topics: Adult; Aged; Alcohol Drinking; Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Sex Factors; Treatment Outcome; Vomiting | 2012 |
Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Isoquinolines; Middle Aged; Nausea; Neoplasm Staging; Palonosetron; Prognosis; Quinuclidines; Serotonin Antagonists; Vomiting | 2013 |
Prolonged inhibition of 5-HT₃ receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization.
Topics: Allosteric Regulation; Animals; Antiemetics; Cell Membrane; Chlorocebus aethiops; COS Cells; Down-Regulation; Endocytosis; Granisetron; Humans; Hydrazones; Isoquinolines; Kinetics; Nystatin; Palonosetron; Protein Transport; Quinuclidines; Radioligand Assay; Receptors, Serotonin, 5-HT3; Recombinant Proteins; Serotonin 5-HT3 Receptor Antagonists | 2013 |
The current status of the use of palonosetron.
Topics: Antineoplastic Agents; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2013 |
Agonists and antagonists induce different palonosetron dissociation rates in 5-HT₃A and 5-HT₃AB receptors.
Topics: Granisetron; HEK293 Cells; Humans; Inhibitory Concentration 50; Isoquinolines; Palonosetron; Protein Subunits; Quinuclidines; Radioligand Assay; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists; Transfection; Tritium | 2013 |
Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives.
Topics: Adolescent; Adult; Antiemetics; Area Under Curve; Contraceptives, Oral; Cross-Over Studies; Drug Interactions; Female; Humans; Isoquinolines; Ketoconazole; Middle Aged; Neurokinin-1 Receptor Antagonists; Palonosetron; Pyridines; Quinuclidines; Randomized Controlled Trials as Topic; Rifampin; Young Adult | 2013 |
[Comparison of antiemesis effects of granisetron, aprepitant and dexamethasone to palonosetron, aprepitant and dexamethasone in treatment of high-emetic risk chemotherapy-induced nausea and vomiting - a retrospective study for efficacy and safety in a sin
Topics: Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug Combinations; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Retrospective Studies; Risk; Vomiting | 2013 |
Separation of palonosetron stereoisomers by electrokinetic chromatography using sodium cholate as chiral selector: comparison of separation modes and elucidation of migration orders.
Topics: Chromatography, Micellar Electrokinetic Capillary; Isoquinolines; Palonosetron; Quinuclidines; Serotonin Antagonists; Sodium Cholate; Stereoisomerism | 2013 |
Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study.
Topics: Adult; Aged; Antiemetics; Aprepitant; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymphoma; Male; Middle Aged; Morpholines; Multiple Myeloma; Nausea; Palonosetron; Pilot Projects; Quality of Life; Quinuclidines; Transplantation, Autologous; Vomiting | 2014 |
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
Topics: Allosteric Site; Animals; Binding Sites; HEK293 Cells; Humans; Isoquinolines; Mice; Molecular Docking Simulation; Mutagenesis, Site-Directed; Palonosetron; Quinuclidines; Radioligand Assay; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists | 2013 |
Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cisplatin; Constipation; Creatinine; Granisetron; Humans; Hydroxyindoleacetic Acid; Intestine, Small; Isoquinolines; Models, Biological; Nausea; Oxazines; Palonosetron; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2015 |
Broad-spectrum antiemetic potential of the L-type calcium channel antagonist nifedipine and evidence for its additive antiemetic interaction with the 5-HT(3) receptor antagonist palonosetron in the least shrew (Cryptotis parva).
Topics: Animals; Antiemetics; Calcium Channel Blockers; Calcium Channels, L-Type; Drug Synergism; Female; Isoquinolines; Male; Nifedipine; Palonosetron; Pyrroles; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Shrews; Vomiting | 2014 |
Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Benzimidazoles; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Japan; Male; Middle Aged; Morpholines; Neoplasms; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Vomiting | 2014 |
Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.
Topics: Adult; Antiemetics; Antineoplastic Agents; Brain Neoplasms; Dexamethasone; Female; Glioblastoma; Humans; Isoquinolines; Male; Medication Adherence; Middle Aged; Nausea; Neoplasms; Palonosetron; Quality of Life; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Translational Research, Biomedical; Treatment Outcome; Vomiting | 2014 |
Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Humans; Injections, Intravenous; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2014 |
Palonosetron versus first-generation 5-hydroxytryptamine type 3 receptor antagonists for emesis prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Cohort Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Middle Aged; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Severity of Illness Index; Transplantation, Homologous; Treatment Outcome; Vomiting; Young Adult | 2014 |
Effect of low concentration sodium dodecyl sulfate on the electromigration of palonosetron hydrochloride stereoisomers in micellar electrokinetic chromatography.
Topics: Chromatography, Micellar Electrokinetic Capillary; Isoquinolines; Micelles; Palonosetron; Quinuclidines; Sodium Dodecyl Sulfate; Stereoisomerism | 2014 |
Netupitant and palonosetron (NEPA): a winning team in the race for the optimal treatment of chemotherapy-induced nausea and vomiting?
Topics: Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2014 |
Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells.
Topics: Acids; Animals; Cell Line; Dose-Response Relationship, Drug; Drug Administration Schedule; HEK293 Cells; Humans; Isoquinolines; Mice; Neuroblastoma; Neurokinin-1 Receptor Antagonists; Palonosetron; Peptide Hydrolases; Protein Binding; Protein Transport; Pyridines; Quinuclidines; Rats; Receptors, Neurokinin-1; Serotonin Antagonists; Time Factors; Tritium | 2014 |
Synergistic effect of 5-hydroxytryptamine 3 and neurokinin 1 receptor antagonism in rodent models of somatic and visceral pain.
Topics: Action Potentials; Administration, Oral; Animals; Colon; Drug Combinations; Drug Synergism; Isoquinolines; Male; Neurokinin-1 Receptor Antagonists; Nociceptive Pain; Palonosetron; Posterior Horn Cells; Pyridines; Quinuclidines; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-1; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Visceral Pain | 2014 |
Therapeutic action of 5-HT3 receptor antagonists targeting peritoneal macrophages in post-operative ileus.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Gastrointestinal Transit; Ileus; Indoles; Isoquinolines; Macrophages, Peritoneal; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neutrophils; Ondansetron; Palonosetron; Postoperative Complications; Quinuclidines; Receptors, Serotonin, 5-HT3; RNA, Messenger; Serotonin; Serotonin 5-HT3 Receptor Antagonists; Tropisetron | 2015 |
Separation mechanisms for palonosetron stereoisomers at different chiral selector concentrations in MEKC.
Topics: Chromatography, Micellar Electrokinetic Capillary; Isoquinolines; Palonosetron; Quinuclidines; Sodium Cholate; Stereoisomerism; Surface-Active Agents | 2015 |
Netupitant-palonosetron combination approved by FDA.
Topics: Antiemetics; Antineoplastic Agents; Drug Approval; Drug Combinations; Drug Interactions; Drug Labeling; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; United States; United States Food and Drug Administration; Vomiting | 2014 |
Differential and additive suppressive effects of 5-HT3 (palonosetron)- and NK1 (netupitant)-receptor antagonists on cisplatin-induced vomiting and ERK1/2, PKA and PKC activation.
Topics: Animals; Antiemetics; Cisplatin; Cyclic AMP-Dependent Protein Kinases; Drug Therapy, Combination; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Isoquinolines; Male; Neurokinin-1 Receptor Antagonists; Palonosetron; Protein Kinase C; Pyridines; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Shrews; Vomiting | 2015 |
Effect of palonosetron (5HT-3 antagonist) and pantoprazole (proton pump inhibitor) against surgical esophagitis induced by forestomach and pylorus ligation in albino rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Arachidonate 15-Lipoxygenase; Biomarkers; Cyclooxygenase 1; Cyclooxygenase 2; Drug Therapy, Combination; Esophagitis; Esophagus; Inflammation; Isoquinolines; Ligation; Palonosetron; Pantoprazole; Proton Pump Inhibitors; Quinuclidines; Rats; Serotonin Antagonists; Stomach | 2016 |
Effects of Palonosetron on Perioperative Cardiovascular Complications in Patients Undergoing Noncardiac Surgery With General Anesthesia: A Retrospective Cohort Study.
Topics: Adult; Aged; Anesthesia, General; Antiemetics; Arrhythmias, Cardiac; Cardiovascular System; Case-Control Studies; Female; Humans; Isoquinolines; Male; Middle Aged; Myocardial Infarction; Palonosetron; Perioperative Period; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists | 2015 |
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Benzodiazepines; Dexamethasone; Half-Life; Humans; Isoquinolines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quality of Life; Quinuclidines; Receptors, Neurokinin-1; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2015 |
Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dexamethasone; Drug Therapy, Combination; Female; Gemcitabine; Granisetron; Humans; Isoquinolines; Kidney Neoplasms; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Vomiting | 2015 |
Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Oxonic Acid; Palonosetron; Prospective Studies; Quality of Life; Quinuclidines; Stomach Neoplasms; Surveys and Questionnaires; Tegafur; Vomiting | 2016 |
[Experience with the use of palonosetron (onicit) in patients with solid tumors receiving cytostatic therapy].
Topics: Antiemetics; Antineoplastic Agents; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Severity of Illness Index; Treatment Outcome; Vomiting | 2015 |
In vitro inhibitory effects of palonosetron hydrochloride, bevacizumab and cyclophosphamide on purified paraoxonase-I (hPON1) from human serum.
Topics: Aryldialkylphosphatase; Bevacizumab; Chromatography, Gel; Cyclophosphamide; DEAE-Dextran; Dextrans; Enzyme Inhibitors; Humans; Isoquinolines; Palonosetron; Quinuclidines | 2016 |
Evaluation of Antiemetic Therapy for Hepatic Transcatheter Arterial Infusion Chemotherapy with Cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Bridged Bicyclo Compounds, Heterocyclic; Catheterization, Peripheral; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Liver; Liver Neoplasms; Male; Middle Aged; Morpholines; Nausea; Oxazines; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2016 |
Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2016 |
Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cisplatin; Female; Genotype; Granisetron; Humans; Isoquinolines; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasm Proteins; Palonosetron; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Quinuclidines | 2017 |
Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of 'overall' nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients.
Topics: Adult; Antiemetics; Antineoplastic Agents; Asian People; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Receptors, Serotonin, 5-HT3; Vomiting | 2017 |
Development and validation of a rapid LC-MS/MS method for simultaneous determination of netupitant and palonosetron in human plasma and its application to a pharmacokinetic study.
Topics: Antiemetics; Chromatography, High Pressure Liquid; Humans; Isoquinolines; Limit of Detection; Liquid-Liquid Extraction; Palonosetron; Pyridines; Quinuclidines; Serotonin Antagonists; Tandem Mass Spectrometry; Time Factors | 2016 |
Prolonged drug-induced myoclonus: is it related to palonosetron?
Topics: Adult; Antiemetics; Female; Humans; Isoquinolines; Myoclonus; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines | 2016 |
Drug in adhesive patch of palonosetron: Effect of pressure sensitive adhesive on drug skin permeation and in vitro-in vivo correlation.
Topics: Adhesives; Administration, Cutaneous; Animals; Isoquinolines; Male; Organ Culture Techniques; Palonosetron; Pressure; Quinuclidines; Rabbits; Random Allocation; Skin Absorption; Transdermal Patch | 2016 |
[Comparative Study of the Antiemetic Palonosetron for Lung Cancer Patients Treated with a Divided Dose of Cisplatin].
Topics: Antiemetics; Cisplatin; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Treatment Outcome; Vomiting | 2016 |
Corrections.
Topics: Arthritis; Capsules; Drug Combinations; Etanercept; Humans; Injections; Isoquinolines; Naltrexone; Nausea; Oxycodone; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Tumor Necrosis Factor-alpha; Vomiting | 2016 |
Palonosetron-5-HT
Topics: Animals; Aplysia; Binding Sites; Carrier Proteins; Crystallography, X-Ray; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Isoquinolines; Membrane Potentials; Models, Molecular; Molecular Structure; Mutation; Palonosetron; Protein Engineering; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists | 2016 |
Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Neoplasms; Dacarbazine; Dexamethasone; Drug Therapy, Combination; Female; Glioma; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Temozolomide; Vomiting | 2016 |
Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study.
Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Dexamethasone; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Morpholines; Nausea; Paclitaxel; Palonosetron; Prospective Studies; Quinuclidines; Vomiting; Young Adult | 2017 |
Comparison of Ramosetron with Palonosetron for Prevention of Postoperative Nausea and Vomiting in Patients Receiving Opioid-Based Intravenous Patient-Controlled Analgesia after Gynecological Laparoscopy.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Benzimidazoles; Electronic Health Records; Female; Gynecologic Surgical Procedures; Humans; Isoquinolines; Laparoscopy; Middle Aged; Pain, Postoperative; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines | 2017 |
Action of Bacopa monnieri to antagonize cisplatin-induced emesis in Suncus murinus (house musk shrew).
Topics: Animals; Antiemetics; Antineoplastic Agents; Bacopa; Cisplatin; Isoquinolines; Male; Palonosetron; Plant Extracts; Quinuclidines; Serotonin Antagonists; Shrews; Tiopronin; Vomiting | 2017 |
Thermodynamic models to elucidate the enantioseparation of drugs with two stereogenic centers by micellar electrokinetic chromatography.
Topics: Chromatography, Micellar Electrokinetic Capillary; Isoquinolines; Micelles; Models, Chemical; Palonosetron; Quinuclidines; Sodium Cholate; Stereoisomerism; Surface-Active Agents; Thermodynamics | 2017 |
Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy.
Topics: Antiemetics; Antineoplastic Agents; Budgets; Cost-Benefit Analysis; Health Resources; Humans; Isoquinolines; Italy; National Health Programs; Nausea; Palonosetron; Pyridines; Quality of Life; Quality-Adjusted Life Years; Quinuclidines; Vomiting | 2017 |
Efficacy of palonosetron to prevent delayed nausea and vomiting in non-Hodgkin's lymphoma patients undergoing repeated cycles of the CHOP regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Palonosetron; Prednisone; Prospective Studies; Quinuclidines; Vincristine; Vomiting; Young Adult | 2018 |
Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP.
Topics: Adult; Aged; Aging; Antibodies, Monoclonal, Murine-Derived; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cyclophosphamide; Doxorubicin; Female; Granisetron; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Palonosetron; Prednisone; Quinuclidines; Risk Factors; Rituximab; Sex Characteristics; Treatment Outcome; Vincristine; Vomiting; Young Adult | 2017 |
Thalidomide reduces chemotherapy-induced vomiting.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Epirubicin; Humans; Isoquinolines; Palonosetron; Quality of Life; Quinuclidines; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome; Vomiting | 2017 |
Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Dexamethasone; Female; Fluid Therapy; Granisetron; Humans; Injections, Subcutaneous; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Practice Guidelines as Topic; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Treatment Outcome; Vomiting | 2018 |
A pilot study with palonosetron in the prophylaxis of radiation-induced nausea and vomiting.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Pilot Projects; Quinuclidines; Radiotherapy; Serotonin Antagonists; Vomiting | 2018 |
Pro-netupitant/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting.
Topics: Administration, Intravenous; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; Radiotherapy; Vomiting | 2018 |
Effect of prophylactic palonosetron and sugammadex on postoperative nausea and vomiting in patients undergoing microvascular decompression under propofol-maintained anesthesia: A retrospective observational study.
Topics: Aged; Anesthesia; Anesthetics, Intravenous; Antiemetics; Decompressive Craniectomy; Drug Therapy, Combination; Female; gamma-Cyclodextrins; Humans; Incidence; Isoquinolines; Logistic Models; Male; Microvascular Decompression Surgery; Middle Aged; Palonosetron; Postoperative Nausea and Vomiting; Preoperative Period; Propofol; Quinuclidines; Retrospective Studies; Risk Factors; Sugammadex; Treatment Outcome | 2018 |
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Pilot Projects; Prospective Studies; Pyridines; Quinuclidines; Receptors, Neurokinin-1; Sarcoma; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2019 |
Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience.
Topics: Antiemetics; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Nausea; Palonosetron; Pyridines; Quality of Life; Quinuclidines; Transplantation, Autologous; Vomiting | 2022 |
Real-world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed-dose combination to prevent chemotherapy-induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Agents; Benzeneacetamides; Dexamethasone; Hematologic Neoplasms; Humans; Nausea; Palonosetron; Piperazines; Pyridines; Quinuclidines; Vomiting | 2022 |
Cost-effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Cost-Benefit Analysis; Dexamethasone; Humans; Nausea; Palonosetron; Quinuclidines; Vomiting | 2022 |
Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cost-Benefit Analysis; Emetics; Humans; Internationality; Nausea; Palonosetron; Quinuclidines; Vomiting | 2022 |
Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Delivery of Health Care; Gastrointestinal Agents; Humans; Nausea; Neoplasms; Palonosetron; Quinuclidines; Retrospective Studies; Treatment Outcome; Vomiting | 2023 |
Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Dexamethasone; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Vomiting | 2023 |
All Eyes on Me, Please: Ocular Palonosetron for the Cancer Patient with Nausea and Vomiting.
Topics: Antineoplastic Agents; Dexamethasone; Humans; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2023 |